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Atherosclerosis is the number one cause of death in the United States and one of the 
most common treatments is the implantation of a stent – a small expandable metal 
scaffold which serves to hold the artery open and maintain proper blood flow.  The two 
most common complications after stenting are restenosis and thrombosis.  In order to 
eliminate these complications, a novel covered stent is investigated.  Covered stents 
could reduce occlusions from restenosis by reducing artery wall prolapse and preventing 
cellular ingrowth without cytotoxic drugs.  Covered stents could reduce thrombosis 
complications by employing a relatively non-thrombogenic material.  Clinical results with 
covered stents to date have been mixed – in part because of material issues.  A covered 
stent membrane should be able to undergo large stretch, prevent restenosis caused by 
smooth muscle cell (SMC) migration, and be relatively non-thrombogenic.  This 
dissertation aims to evaluate polyvinyl alcohol (PVA) cryogels for covered stents in terms 
of their mechanics, ability to prevent restenosis, and thrombogenicity. 
Mechanical testing included uniaxial tensile testing, puncture testing, and the fabrication 
and expansion of PVA cryogel covered stents.  Uniaxial testing results showed PVA 
cryogels to have sufficient ultimate stretch which was similar to bare metal stents during 
deployment.  Puncture testing revealed that PVA cryogels are highly resistant to this 
failure mechanism and not likely to puncture in vivo.  PVA cryogel covered stents were 
examined visually and by environmental scanning electron microscope after expansion.  
No tears were seen in the membrane which was much thinner than the stent struts and 
therefore not likely to increase crimped profile greatly. 
xviii 
 
Finite element analysis of PVA cryogel covered stents was used to determine the 
membrane’s effect on artery wall stress.  PVA cryogel covered stents were able to 
reduce both artery wall stress and tissue prolapse when compared to equivalent 
uncovered stents.  Migration assays were used to determine if PVA cryogels are able to 
block the SMC migration seen during restenosis.  PVA cryogels significantly reduced 
SMC migration in modified Boyden chambers – suggesting that they would be able to 
prevent restenosis in vivo. 
Thrombogenicity was tested in vitro with a gravity-fed flow loop using porcine blood and 
in vivo with a sheep model.  PVA cryogels were found to be less thrombogenic than 
polyester controls in terms of flow rate and amount of thrombus deposited with the flow 
loop system.  The sheep study demonstrated the feasibility of implanting PVA cryogel 
covered stents.  After explantation of the covered stents, no gross inflammation or 
fibrotic response was observed.  Additionally, the PVA cryogel membranes were intact – 
providing in vivo evidence for the durability of PVA cryogel covered stents.  
Overall, this work provides evidence that covered stents made with PVA cryogels are a 
feasible device in terms of their mechanics, ability to prevent restenosis, and low 
thrombogenicity.  PVA cryogel covered stents may be able to prevent both restenosis 
and thrombosis.  This work represents a major advancement in the development of PVA 









1.1 Atherosclerosis & Current Treatments 
Cardiovascular disease has been the number one cause of death in the United States 
since 1919 with coronary heart disease and stroke, caused by underlying 
atherosclerosis, accounting for over two thirds of those deaths [1].  Commonly known as 
‘hardening of the arteries,’ atherosclerosis is characterized by fatty buildups, atheromata, 
along the artery wall that lead to plaque formation and loss of elasticity.  It is a slow, 
progressive disease that begins in childhood and leads to the formation of atheromata in 
the aorta, medium, and large sized arteries.  Atherosclerotic lesions are classified by the 
American Heart Association from a Type I initial lesion to a Type VI complicated lesion 
[2].  Stenoses in the arteries leading to the heart and brain limit blood flow and can 
cause death.   
Treatments for atherosclerosis depend on the location of the lesion, its classification, 
and other patient dependent factors including family history, smoking, etc.  These 
treatments may include lifestyle changes, medication, percutaneous transluminal 
angioplasty, stent implantation, other catheter-based treatments, or vascular surgery.  
Two separate studies in 1994 showed that the placement of stents, expandable metal 
scaffolds delivered via catheter, in the coronary arteries improved vessel patency over 
angioplasty alone (32% vs. 22% at seven months and 42.1% vs. 31.6% at six months) 
and since then, stenting has become one of the most common treatments for 
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atherosclerosis [3-5].  The two most problematic complications associated with stenting 
are restenosis and thrombosis [6].   
1.2 Restenosis & Thrombosis 
Restenosis is the process by which a treated vessel’s luminal diameter decreases in size 
over a period of time, usually six months to a year, and occurs in approximately 20 – 
45% of bare metal stents depending on risk factors such as diabetes, number of stents, 
and stent length among others [7-9].  Restenosis is typically defined as a 50% or greater 
reduction in diameter by angiogram [10].  While restenosis can be caused by elastic 
recoil or negative remodeling, in-stent restenosis is usually caused by neointimal 
hyperplasia [11].  During neointimal hyperplasia, vascular smooth muscle cells migrate 
from the media to the intima where they begin to proliferate and produce large amounts 
of extracellular material [12].  As the neointimal layer grows, it reduces the lumen size 
and blood flow through the affected area.  Restenosis is a significant clinical problem 
which leads to a large number of repeat procedures and hospitalizations [13].   
Thrombosis is the process of blood clot formation and in-stent thrombosis can be a very 
serious problem as occlusive clots can form rapidly [14, 15].  For bare metal stents, the 
risk of stent thrombosis is now less than 2% (at one month) mostly due to the practices 
of high balloon inflation pressure to ensure proper stent apposition and dual anti-platelet 
therapy, i.e. aspirin and ticlopidine [16-18].  Although drug-eluting stents have decreased 
restenosis rates by a relative 50% to 80% [11], concerns are now being raised about an 
increased risk of late (greater than one year after implantation) stent thrombosis [19, 20].  
Given the high associated mortality rate, 45% at 9-month follow-up in a recent study of 
paclitaxel- and sirolimus-eluting stents [21], significant research efforts are being made 
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to understand the causes of late stent thrombosis and create less thrombogenic stent 
materials [14, 22, 23].   
1.3 Developments in Stent Technology 
Drug-eluting stents are made by coating a bare metal stent with a polymer which 
contains an anti-proliferative drug, e.g. sirolimus or paclitaxel, intended to disrupt smooth 
muscle cell proliferation [24].  While drug-eluting stents have been successful in the 
coronary arteries [24], that success has not been duplicated in the periphery where the 
need for innovative new treatments is great [25].  As already mentioned, drug-eluting 
stents have been drawing criticism lately because they may have an increased risk of 
late-stent thrombosis when compared to bare metal stents [19].  Late-stent thrombosis in 
drug-eluting stents could be caused by a delayed endothelialization process [22].  One 
recent study showed that while bare metal stents were completely endothelialized in 6 to 
7 months, drug-eluting stents had not completely endothelialized by 40 months [22].  
The cessation of anti-platelet therapy has been shown to be a significant risk factor for 
late stent thrombosis [22], but there is still no consensus on the appropriate duration of 
anti-platelet therapy after drug-eluting stent implantation [20]. 
Bioabsorbable stents are another active area of research.  Bioabsorbable stents may 
help reduce chronic inflammation, eliminate the need for prolonged anti-platelet therapy, 
and lower the risk of thrombosis complications by eroding away once the acute phase 
after stent implantation (when mechanical support is required to maintain patency) has 
passed [26, 27].  The two materials which have been investigated most for 
bioabsorbable stents are magnesium alloy and poly-L-lactic acid [26].  Bioabsorbable 
stents hold promise as a future treatment, but the problems of low radial force and 
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variable degradation rates must still be solved before this treatment can become a reality 
[27, 28]. 
Biomechanical factors affecting artery wall stress are of great importance.  Kastrati et al. 
has shown that stent design can have a profound effect on clinical restenosis rates [29].  
Finite element analysis can be a powerful tool for investigating stent and artery 
interactions.  Artery wall stress, which is affected by stent design, is also related to tissue 
prolapse – an inward draping of tissue which can reduce lumen diameter by up to 20% 
[30].  Several studies have used finite element analysis to compare different stent 
designs and their effect on vessel stresses and tissue prolapse [31, 32].  One recent 
investigation has demonstrated a link between high artery wall stress and high clinical 
restenosis rates [33], highlighting the need for biomechanical analyses when new stents 
are being designed.   
1.4 Covered Stents as a New Treatment Modality 
Covered stents are made by combining a bare metal stent with a membrane material, 
e.g. poly[tetrafluoroethylene] (PTFE), poly[ethylene terephthalate] (polyester or trade 
name DacronTM), silicone, or salmon collagen, which covers the gaps (cells) between 
stent struts [34-37].  While covered stents have typically been used in vessel repair 
situations or aneurysm repair, they are now being considered as a treatment for 
atherosclerosis [28].  Covered stents have the potential to block the vascular smooth 
muscle cell migration seen during neointimal hyperplasia with a physical barrier and 
without cytotoxic drugs, thereby reducing in-stent restenosis complication rates [37-39].  
If the membrane were made of a non-thrombogenic material, complications from 
thrombosis could be minimized as well.  Materials which have been used for covered 
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stent membranes implanted in humans include PTFE and polyester [28].  Initial results 
with polyester covered stents, however, were disappointing due to low patency, high 
thrombosis rates, and significant inflammatory response [40-42].  Most industry effort 
since then has focused on expanded PTFE (ePTFE) covered stents [28].  Covered 
stents with ePTFE have had success in longer superficial femoral artery lesions in 
patients with decent inflow and runoff status [43], although they generally are not used in 
smaller diameter vessels because of thrombosis concerns [44].   
In addition to preventing complications from restenosis and thrombosis, covered stent 
membranes must also be mechanically suitable.  During deployment, stents deform such 
that their diameters increase to between 2.7 and 4.6 times their crimped size [45].  
Covered stent membranes should also be able to expand similarly in order to maintain a 
reduced device profile and avoid membrane tearing problems.  Additionally, covered 
stent membranes should be able to resist puncture because this failure mode could lead 
to membrane embolization and the blockage of a downstream vessel.  To the author’s 
knowledge, there are currently no materials available that meet all these mechanical 
requirements and are able to prevent restenosis and thrombosis. 
1.5 Polyvinyl Alcohol Cryogels 
Polyvinyl alcohol (PVA) is a polymer with a hydrophilic hydroxyl side group and has been 
used safely in medical applications, e.g. contact lenses, for many years.  PVA cryogels 
are a new class of biomaterial which offer more strength than a typical hydrogel and 
have water content similar to human soft tissue [46].  By varying the percent weight 
PVA, molecular weight of the PVA, number of freeze/thaw cycles, or the cycle duration, 
one can control the mechanical properties of the material making it stronger, stiffer, or 
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more porous as required [47].  In general, the material has similar strength to native soft 
tissue [46, 48].  This material, developed at Georgia Tech and protected under US 
patents 5,981,826 and 6,231,605 [46, 48], is now sold under the trade name SalubriaTM 
and has been used by SaluMedica, LLC, Carticept, Inc., Mimedx, Inc., and Arthrex, Inc. 
in medical devices implanted in humans for nine years without any medical device 
reports.  PVA cryogels have been shown to be approximately 50 times more compliant 
than polyester or PTFE [49] and may therefore be mechanically suitable for covered 
stent membranes.  Additionally, one study has shown that important cell adhesion 
proteins do not readily adsorb onto PVA hydrogels [50].  This prevented cells from 
attaching to the material –suggesting that PVA cryogels may be able to prevent both 
restenosis and thrombosis.  
1.6 Specific Aims 
A stent covered with a non-thrombogenic membrane could prevent restenosis from 
neointimal hyperplasia and thrombosis.  However, the membrane material must also be 
able to expand reliably on a stent.  PVA cryogels are a promising class of biomaterials 
which could provide these functions.  By demonstrating that these design objectives can 
be met, this dissertation will provide important pre-clinical feasibility and safety 
information for future animal and clinical trials through the following three specific aims. 
I. Evaluate PVA cryogels mechanically for covered stent applications in terms 
of their ultimate stretch, puncture resistance, and ability to handle the 
crimping and expansion processes. 
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Ultimate stretch is evaluated through uniaxial tensile testing of ring segments while 
puncture testing is done with a modified ASTM method.  PVA cryogel covered stents are 
fabricated by hand, crimped down, expanded on a balloon catheter, and then inspected 
for defects. 
II. Characterize the capacity of biomaterial membranes to reduce restenosis 
with computational and biological models. 
Finite element analysis is employed to evaluate the capacity of covered stent 
membranes to reduce tissue prolapse and artery wall stress.  Modified Boyden 
chambers are used to evaluate the ability of PVA cryogel membranes to reduce vascular 
smooth muscle cell migration. 
III. Evaluate biomaterial thrombogenicity through in vitro and in vivo testing.   
For in vitro testing, gravity fed flow loops with porcine blood are used.  In vivo testing is 
done with a sheep model as part of a study on prosthetic vein valves for chronic venous 
insufficiency. 
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PART 1:  





Uniaxial Tensile Testing of Polyvinyl Alcohol Cryogels 
 
2.1 Background 
2.1.1 Bare Metal Stents 
Treatment for atherosclerosis was revolutionized in the late 1970s with the invention of 
percutaneous transluminal coronary angioplasty (PTCA) by Andreas Grüntzig, which 
allowed for non-surgical management of atherosclerotic plaques.  The next major 
change in treatment came in the 1990s when bare metal stents (BMS) were introduced 
and shown to be superior to PTCA alone in two clinical trials [1, 2].  BMS are small metal 
scaffolds that are delivered to the lesion site via catheter and deployed by either a 
balloon or a self-expansion mechanism.  Typical BMS expand to 2.7 to 4.6 times their 
crimped diameter during deployment [3].  Although new types of stents have been 
introduced, complications from restenosis and thrombosis persist [4, 5].  Research on 
new stent designs and materials continues to be very active [6, 7].   
2.1.2 Polyvinyl Alcohol Cryogels 
Polyvinyl alcohol (PVA) is a polymer with a hydrophilic hydroxyl side group that has been 
used safely in medical applications, e.g. contact lenses, for many years.  PVA cryogels 
are a new class of biomaterial which offer more strength than a typical hydrogel and 
have water content similar to human soft tissue [8].  By varying the percent weight PVA, 
molecular weight of the PVA, number of freeze-thaw cycles, or the cycle duration, one 
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can control the mechanical properties of the material making it stronger, stiffer, or more 
porous as required [9].  Greater control over the final mechanical properties makes PVA 
cryogels an ideal choice for covered stents because it gives the design engineer the 
ability to meet multiple design constraints at the same time by adjusting manufacturing 
parameters.  In general, the material has similar strength to native soft tissue [8, 10].  
This material, developed at Georgia Tech and protected under US patents 5,981,826 
and 6,231,605 [8, 10], is now sold under the trade name SalubriaTM.   
2.1.3 Uniaxial Tensile Testing 
Uniaxial tensile testing of ring segments provides important information on mechanical 
properties such as ultimate stress, ultimate stretch, and modulus of elasticity.  This 
method has been used to study both arteries and synthetic materials [11, 12].  Testing of 
ring segments is preferred over dumbbell sections to avoid problems with slipping or 
tearing near the grips of a dumbbell test [11, 13].  Biaxial testing can also provide useful 
information of mechanical properties, but was deemed unnecessary since complete 
constitutive models for PVA cryogels can be generated with uniaxial test data [14, 15]. 
2.2 Methods 
2.2.1 PVA Cryogel Ring Segment Preparation 
PVA (Air Products and Chemicals, Inc.) was dissolved in deionized water until it was 
completely solubilized by employing a combination of heat and pressure as described by 
Ku et al. [8].  Two different percent weight, wt%, formulations were prepared at 10% and 
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20% according to Equation 2.1 where mPVA is the mass of PVA in grams and VH2O is the 










        (2.1) 
These formulations were chosen as practical low and high percent weights; formulations 
outside of this range can be used, but were deemed unlikely to have the desired 
mechanical characteristics a priori.  Once prepared, the solutions were mixed to ensure 
uniformity and injected into tubular molds.  The mold and solution were then placed in a 
sealed container to prevent water evaporation and subjected to four freeze-thaw cycles 
in order to solidify the cryogel.  After thermal cycling, the newly formed cryogel tubes 
were removed from the mold and cut into ring segments of appropriate length for each 
test.  Each ring segment was individually imaged alongside a reference object of known 
size as in Figure 2.1.  Each ring segment’s dimensions were determined by comparing 
the number of pixels of the desired dimension to the reference object using either GNU 
Image Manipulation Program (GNU Project) or ImageJ (National Institutes of Health) 
software.  Each dimension was measured three times and the average is reported.  Ring 




Figure 2.1: Sample measurement photos of a PVA cryogel ring segment from front (left) 
and side (right). 
 
2.2.2 Calculating Stress  
Stress in the ring segment is calculated as previously described [11].  To begin, the 
volume of the stretched ring segment is calculated by  




−=−−=      (2.2) 
where Vf is final (or current) volume, ℓ is length, do is final outer diameter, and h is 
thickness.  Cross-sectional area is defined as 
lhA 2= .         (2.3) 
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where Ci and Cf are the initial and final circumference, Do is the initial (unexpanded) 
outer diameter, and a0 (hook diameter) and b (separation distance) are as shown as in 
Figure 2.2. 
Assuming material incompressibility [14, 15], the initial volume can be set equal to the 
final volume.  By eliminating small terms (less than 5% of the total numerical value), the 






.         (2.5) 
Cauchy stress can then be calculated by dividing the measured force, f, by the final 




λσ = .         (2.6) 
2.2.3 Uniaxial Tensile Testing 
A total of 36 ring segments were prepared, 18 of 10% PVA and 18 of 20% PVA.  
Dimensions for the segments were as follows: outer diameter ranged from 3.47 mm to 
4.84 mm; thickness ranged from 100 µm to 280 µm; and length was between 2.73 mm 
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and 4.73 mm.  Specialized hook fixtures were created to stretch the samples in an 
ElectroForce 3200 mechanical tester (Bose Corporation) with a 5 lb load cell as shown 
in Figure 2.3.  The ring segments were placed onto the hook fixtures which were moved 
to a position that corresponded to a stretch ratio of 1.0.  The test began by holding one 
hook stationary while the other advanced at a rate of either 0.1 mm/s or 1.0 mm/s until 
the ring segment broke. The two test speeds were chosen as reasonable lower and 
upper limits of expansion rates to which a membrane could be exposed during stent 
expansion.  Nine samples of each formulation were tested at each speed and kept 
hydrated by a drip of deionized water.  Force and displacement were continuously 
measured with Wintest software and exported to a data file after every test.  All statistical 
analyses (ANOVA and ANCOVA with significance set at 0.05) were completed with 
SPSS Statistics 17.0 (SPSS Inc.). 
 
 
Figure 2.2: Diagram of stretched ring segment with dimensions labeled.  
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Length, ℓ

















































Stress-strain behavior of the PVA cryogel ring segments was non-linearly elastic with 
strain hardening similar to arterial tissue.  Figure 2.4 shows typical loading scenarios for 
both a 10% and 20% PVA cryogel at the test speed of 0.1 mm/s and their relation to 
typical BMS expansion.  The average PVA cryogel ring segment ultimate stretch ratio fell 
within the lower range of typical BMS stretch ratios.  The ultimate strength of all samples 
ranged from 500 kPa to 6700 kPa depending on the percent weight formulation.  The 
ultimate stress of the 20% PVA cryogel was significantly higher than the 10% PVA 
cryogel regardless of test speed (p<0.05).  There was no statistically significant 
difference in ultimate stress between test speeds for either PVA formulation.  Ultimate 
stretch ratios were similar across all variables tested.  The 10% and 20% formulations 
both had ultimate stretch ratios of approximately 3.0.  The only statistically significant 
difference was that the 20% PVA cryogel had a lower ultimate stretch ratio of 2.74 at the 
faster speed of 1.0 mm/s when compared to the slower test speed of 0.1 mm/s (p<0.05).  
Secant elastic moduli, Esec, were calculated from stretch ratios of 1.0 to 1.5.  Overall, the 
membranes increased in stiffness with increasing percent weight PVA and increasing 
test speed (p<0.05).  The samples were not randomly distributed between sample 
groups based on the dimensions.  In order to account for this, dimensions were included 
in the statistical analysis as covariates.  See Table 2.1 for a complete breakdown of 






Figure 2.4: Typical stress-stretch ratio curves during uniaxial tensile testing of a 10% 
and 20% PVA cryogel ring segment (both at 0.1 mm/s).  The ultimate stretch ratios fall 
within the lower half of typical BMS expansion range. 
 
Table 2.1: Uniaxial tensile test results by percent weight PVA and test speed. 
 Test Speed (mm/s) 10% PVA 20% PVA 
σult (kPa) 0.1 1200 ± 500 3500 ± 1500* 
 1.0 1700 ± 810 2800 ± 1100* 
λult (-) 0.1 3.03 ± 0.28 3.08 ± 0.28 
 1.0 3.08 ± 0.44 2.74 ± 0.18† 
Esec (kPa) 0.1 110 ± 65 360 ± 130* 
 1.0 140 ± 58 490 ± 130*† 
Mean ± one standard deviation.  * is statistically different from 10% PVA at same test 
speed, p<0.05.  † is statistically different from 0.1 mm/s at same percent weight PVA, 





Thin PVA cryogel ring segments had relatively high ultimate stretch ratios of 
approximately 300%.  Since typical BMS stretch ratios are of the same magnitude, it is 
expected that PVA cryogels could serve as covered stent membranes, capable of 
stretching with a BMS during deployment.  While one group of PVA cryogel ring 
segments tested (20% PVA at 1.0 mm/s) did have a slightly lower ultimate stretch ratio 
(274%), they still fell within the typical values for BMS and are thus deemed acceptable.  
The secant elastic modulus calculated over a potential working range is similar to 
measurements of elastic moduli of human arteries [16, 17].  The matching of elasticity 
could reduce restenosis caused by compliance mismatch as the mechanical properties 
of the membrane are similar to those of the surrounding tissue – a problem seen in 
vascular grafts [18].   
Thick PVA cryogels have been shown previously to have ultimate stretch ratios greater 
than 300% [11] and thin PVA cryogels are shown here to have similar ultimate stretch 
ratios.  The two materials currently used as synthetic vascular grafts – 
poly[tetrafluoroethylene] (PTFE) and poly[ethylene terephthalate] (polyester or trade 
name DacronTM) – are generally known to be stiff and noncompliant [13], although some 
expanded PTFE (ePTFE) materials are now being made with higher ultimate stretch 
values [19].  For covered stent applications, a compliant membrane that is able to stretch 
with the metal of a BMS has the potential to reduce the crimped device profile.  This 
property has enormous potential as it improves deliverability – an extremely important 
parameter for surgeons when implanting stents in tortuous vessels.  The PVA cryogel 
membranes tested here were of approximately the same thickness as a stent strut [6] 
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and are thus not expected to increase device profile greatly when compared to 
uncovered BMS. 
One limitation of the present study is that while the PVA cryogel ring segments did 
expand to approximately the same amount as typical BMS, they fell within the lower half 
of that range.  Given the current manufacturing techniques, these PVA cryogels would 
likely fail mechanically in a stent that required larger stretch.  Several factors are known 
to affect the final mechanical properties of this material, including molecular weight and 
number of thermal cycles, and these parameters could be adjusted in order to achieve 
higher ultimate stretch [8, 20].  Alternatively, a PVA cryogel covered stent could be 
designed such that the membrane was not required to stretch large amounts.  By 
covering a BMS in an expanded or partially-expanded state, and then crimping it onto a 
catheter, the PVA cryogel material would not be required to stretch as much as the metal 
during deployment.  Several PVA cryogel covered stents have been made using this 
technique and a full description is given in Chapter 4.   
In conclusion, the PVA cryogel ring segments tested had high ultimate stretch ratios and 
appear to be mechanically capable of expanding with a stent during deployment.  The 
ring segments tested were approximately as thick as a stent strut and are therefore not 
expected to increase the crimped device profile.  Furthermore, given the material’s 
compliant nature, PVA cryogel covered stents may be able have smaller crimped profiles 
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Puncture Testing of Polyvinyl Alcohol Cryogels 
 
3.1 Background 
3.1.1 Puncture Risk 
The inclusion of membranes which could detach from the metal portion of covered stents 
introduces a risk of membrane embolization not present with regular bare metal stents.  
In order to mitigate this risk, which could lead to the blockage of downstream vessels, a 
membrane material must be strong enough to withstand various mechanical insults 
without failing.  One potential mechanical insult is puncture by either a stent strut or an 
atherosclerotic plaque.  Membrane puncture would cause a tear that could lead to 
portions of the membrane separating from the stent, traveling downstream, and 
becoming lodged in smaller vessels.   
3.1.2 Puncture Testing 
Puncture testing is a common mechanical test that is performed in several industries 
including food and textile [1-3].  Puncture testing has also previously been used on 
vascular prostheses as a measure of “suturability” [4].  While test methods vary slightly 
based on application, all puncture tests consist of a membrane which is held in place 
while a probe of known size is advanced towards the membrane.  Force and 
displacement are measured continuously while the probe is in contact with the 
membrane, which may or may not rupture depending on the parameters of the test.  
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During deployment, a covered stent membrane would displace from the vessel center to 
its edge.  Thus, the deployed covered stent radius should represent a maximum value 
for displacement and is chosen as a minimum safety requirement against this failure 
mode.  In the present study, the safety requirement for puncture resistance was set as a 
push-through displacement equal to the radius of the test mandrel on which the PVA 
cryogel ring segment specimens were held in place.   
3.2 Methods 
3.2.1 PVA Cryogel Ring Segment Preparation 
PVA cryogel ring segments for puncture testing were prepared and measured by the 
same method as those used in the uniaxial tensile testing (Section 2.2.1).  The only 
difference between the ring segments used in the puncture testing versus those used in 
the uniaxial tensile testing was that length was not measured in this study.  For puncture 
testing, the samples only had to be long enough to cover the transverse hole and fit into 
the test apparatus (approximately 10 mm).   Sample outer diameters ranged from 4.05 
mm to 5.37 mm while the thickness ranged from 110 µm to 350 µm.   
3.2.2 Puncture Testing 
The puncture test method employed here was modified for covered stent membranes 
from an ASTM standard on the puncture testing of geotextiles [1].  PVA cryogel ring 
segments were placed onto a cylindrical mandrel which had a transverse hole drilled 
through the center; the area of the transverse hole (7.16 mm2 or 8.04 mm2) is typical of 
the area between adjacent expanded stent struts [5].  The diameter of the mandrel, 7.80 
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mm, was chosen in order to give the ring segments a circumferential stretch ratio 
between 1.5 and 2.0 – values that are expected to be within design constraints for a 
PVA cryogel covered stent.  The sample was held stationary with vice grips while a 
cylindrical probe advanced towards the sample at a rate of 1 mm/s on an ElectroForce 
3200 mechanical tester (Bose Corporation) with a 5 lb load cell as shown in Figure 3.1.   
Every test began with the probe slightly above the test sample; the point of zero 
displacement was determined post hoc by noting the location where the load first started 
to increase.  Each test was run until the ring segment was punctured.  Six 10% and six 
20% PVA cryogel ring segments were tested twice each (the two puncture sites were 
located 180° apart around the circumference) for a total of 24 tests.  Two different 
diameter probes (0.84 mm and 1.37 mm) were used to represent two different sized 
objects which could puncture the membrane.  These probe diameters were chosen in 
order to maintain an approximate ratio of 1:3 between the probe diameter and the 
transverse hole diameter (3.02 mm or 3.20 mm) to be consistent with ASTM guidelines 
and previous investigations on puncture strength [1, 6].  Force and displacement 
measurements were recorded during each test with Wintest software and exported to a 





Figure 3.1: Close-up view of puncture test apparatus. 
 
Puncture pressure was calculated by dividing the load by the cross-sectional area of the 
transverse hole.  It is reported in mmHg and is expected to be a worst case means of 
comparison for extraluminal pressure.  The puncture pressure represents the worst case 
loading scenario as it is a point load from the probe and not distributed across the entire 
transverse hole area.  Fractional displacement is calculated by dividing the actual 
displacement by the test mandrel radius (3.90 mm) such that a value of 1.00 represents 
the pre-determined safety requirement.  Membrane stiffness is reported in terms of the 
push-through load over thickness and as the push-through displacement over thickness.  




PVA cryogel ring segments met the pre-determined safety requirement of a push-
through displacement greater than the radius of the test mandrel as seen in Figure 3.2.  
The 95% confidence interval of the push-through displacement was from 4.55 mm to 
5.00 mm and exceeded the safety requirement of 3.9 mm.  The average fractional push-
through displacement was 1.22 ± 0.14 for all PVA cryogel membranes tested.  Figure 
3.3 shows the general shape of the load-displacement curve for two sample PVA cryogel 
ring segments.  The only variable found to have a statistically significant effect on push-
through displacement was probe diameter.  The larger probe diameter had a larger 
push-through displacement which was significant at the p<0.05 level (4.56 mm vs. 4.99 
mm).  Fractional push-through displacement was the only other variable for which probe 
diameter achieved statistical significance, see Table 3.1 for a complete breakdown of all 
relevant variables by probe diameter.   
 
 
Table 3.1: Puncture test results by probe diameter. 
 0.84 mm 1.37 mm 
Push-Through Displacement (mm) 4.56 ± 0.35 4.99 ± 0.61* 
Fractional Push-Through Displacement (-) 1.17 ± 0.09 1.28 ± 0.16* 
Push-Through Displacement / Thickness (-) 25.26 ± 4.04 27.02 ± 10.49 
Push-Through Load (N) 0.39 ± 0.12 0.47 ± 0.25 
Push-Through Load / Thickness (N/mm) 2.18 ± 0.77 2.19 ± 0.58 
Push-Through Puncture Pressure (mmHg) 387.4 ± 119.3 463.7 ± 234.5 




Figure 3.2: Push-through displacement versus membrane thickness for all puncture 
tests.  The dashed line represents the pre-determined safety requirement. 
 
Although there was no statistically significant difference in push-through displacement 
for percent weight PVA, 20% PVA did trend towards a larger push-through displacement 
value.  Push-through displacement did not correlate with membrane thickness within the 
range tested as can be seen in Figure 3.2 (r=0.243, p=0.252).  The 20% PVA 
formulation was stronger and stiffer than the 10% PVA formulation in that it had 
significantly larger push-through load, push-through puncture pressure, and push-
through load over thickness (p<0.05).  A complete breakdown of the relevant variables 
by percent weight PVA is given in Table 3.2.  Test samples were not distributed 
randomly based on their stretch ratio or membrane thickness.  To account for this, 
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stretch ratio was included as a covariate in the statistical analyses for those variables 
that it correlated with: puncture pressure (r=0.570, p=0.004), push-through displacement 
over thickness (r=0.708, p<0.001), and push-through load (r=-0.558, p=0.005).  
Membrane thickness was included as a covariate for both puncture pressure (r=0.624, 




Figure 3.3: Puncture pressure (force over cross-sectional hole area) versus probe 
displacement for two typical PVA cryogels.  A fractional displacement of 1.0 is set as the 
safety requirement against puncture failure. 
33 
 
Table 3.2: Puncture test results by percent weight PVA. 
 10% PVA 20% PVA 
Push-Through Displacement (mm) 4.65 ± 0.35 4.90 ± 0.66 
Fractional Push-Through Displacement (-) 1.19 ± 0.09 1.26 ± 0.17 
Push-Through Displacement / Thickness (-) 30.08 ± 7.79 22.20 ± 5.78 
Push-Through Load (N) 0.28 ± 0.04 0.58 ± 0.17* 
Push-Through Load / Thickness (N/mm) 1.81 ± 0.41 2.56 ± 0.67* 
Push-Through Puncture Pressure (mmHg) 282.2 ± 47.4 425.6 ± 18.6* 
Mean ± one standard deviation.  * is statistically different from 10% PVA, p<0.05. 
 
3.4 Discussion 
Puncture testing has been used previously in many industries.  Since covered stent 
membranes could puncture, embolize, and become lodged downstream, it is necessary 
to test PVA cryogels for puncture resistance before using them as covered stent 
membranes.  The results of the present study show that PVA cryogel membranes are 
able to resist puncture to a pre-determined safety requirement, i.e. a push-through 
displacement greater than the radius of the test mandrel.  For example, if the same ring 
segments had been placed onto a stent on a 9 Fr catheter and expanded to a diameter 
of 7.8 mm (the same as the test mandrel), on average they would have a factor of safety 
of approximately 2.0 against puncture failure.  As expected, 20% PVA cryogels were 
stiffer and had a larger push-through load,  push-through load over membrane thickness, 
and push-through puncture pressure than 10% PVA cryogels [7, 8].  No statistically 
significant difference was seen for push-through displacement between PVA 
formulations, although the 20% PVA cryogels did trend towards a higher value.  Within 
the range tested, push-through displacement did not depend on membrane thickness.  
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Therefore, membranes as thin as 110 µm may be used without loss of puncture 
resistance.     
The general shape of the puncture pressure-probe displacement curve (Figure 3.3) 
agrees well with the sample curve from the ASTM puncture testing standard [1] which 
gives the test method employed here validity.  One limitation of the present study is that 
PVA cryogel ring segments were used and PVA cryogel covered stents were not.  While 
the use of covered stents instead of ring segments is not expected to change the results 
significantly, it would provide a more realistic approximation of the in vivo case.  Once a 
PVA cryogel covered stent design has been fixed, a second round of puncture testing is 
recommended to ensure that PVA cryogel covered stents have the same puncture 
resistance as PVA cryogel ring segments. 
In conclusion, the results presented here show that PVA cryogel ring segments possess 
sufficient puncture strength to not tear and embolize based on the pre-determined safety 
requirement.  Based on these findings, either PVA formulation would be acceptable 
although 20% PVA cryogels may be preferred in order to provide a stiffer membrane 
towards puncture insults and because they trended towards a higher push-through 
displacement.  Lastly, push-through displacement did not depend on membrane 
thickness within the range tested (110 µm to 350 µm), allowing for a reduced crimped 
profile and increased deliverability with no loss of puncture resistance. 
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PVA Cryogel Covered Stent Fabrication & Expansion 
 
4.1 Background 
4.1.1 Covered Stent Uses 
Covered stents are typically made by combining a bare metal stent (BMS) with a 
membrane that spans the open areas between stent struts.  Until recently, stent grafts 
and covered stents had been used mainly in vessel repair situations such as aneurysm 
or traumatic injury [1].  Today, covered stents are being investigated as a treatment for 
occlusive atherosclerosis [2-5].  Covered stents have the potential to prevent the 
vascular smooth muscle cell migration seen during in-stent restenosis with a physical 
barrier [6-8].  Poly[tetrafluoroethylene] (PTFE) and poly[ethylene terephthalate] 
(polyester or trade name DacronTM) are two potential choices for covered stent 
membranes given their success as synthetic vascular grafts [9].  Initial results with 
polyester covered stents, however, were disappointing due to high complication rates 
and low patency [10-12].  Since then, most industry effort has focused on PTFE or 
expanded PTFE (ePTFE) covered stents [1].  While progress has been made in ePTFE 
stents, they have not been as widely accepted as drug-eluting stents and can suffer from 
thrombosis problems at small diameters [13], similar to how small diameter PTFE 
vascular grafts have lower patency than large diameter grafts [14]. 
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4.1.2 Covered Stent Clinical Trials 
Covered stents have undergone several clinical trials in various regions including the 
coronary arteries, superficial femoral artery (SFA), and femoropopliteal arteries.  Some 
of these results are summarized briefly here.  The Jostent is a balloon-expandable 
covered stent made by sandwiching a PTFE membrane between two BMS [8] resulting 
in a device which is thicker than an equivalent uncovered stent.  The RECOVERS trial 
compared the Jostent and BMS in the treatment of saphenous vein grafts of the 
coronary arteries.  After 6 months, there was no statistically significant difference 
between the two groups in terms of restenosis rates and major adverse cardiac event 
rates, but the Jostent group did have a higher incidence of non-Q-wave myocardial 
infarction (12.8% versus 4.1%, p=0.013) [5].  The authors believe this difference may 
have been caused by a delayed endothelialization process which predisposed the PTFE 
covered stents to thrombotic occlusion.   
The Viabahn endoprosthesis, formerly known as the Hemobahn endoprosthesis, was 
given FDA approval in 2005 for implantation in the SFA [1].  The Viabahn 
endoprosthesis is a self-expanding device which consists of an ePTFE lining with a 
nitinol stent externally mounted along its entire length [1].  Kedora et al. recently 
compared the use of the Viabahn endoprosthesis with synthetic (DacronTM or ePTFE) 
femoral-popliteal bypass in the treatment of SFA occlusive disease in 100 limbs in 86 
patients [3].  The study found no significant differences in primary or secondary patency 
between the two groups.  Primary patency was 84%, 82%, 75.6%, and 73.5% for the 
stent graft group and 90%, 81.8%, 79.7%, and 74.2% for the bypass group at 3, 6, 9 and 
12 months of follow-up.  They conclude that the two treatment modes are comparable 
and recommend longer follow-up to determine ongoing efficacy.  While this study 
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showed favorable results for the Viabahn endoprosthesis, other studies have shown 
highly variable results with six month primary patency ranging from 49% (18 patients) to 
90% (80 limbs) at six months [2, 4].  The VIBRANT (Viabahn veRsus bAre Nitinol stenT) 
trial seeks to understand the differences between placement of an ePTFE covered stent 
versus an equivalent BMS in long femoropopliteal lesions.  Enrollment in this study was 
completed at the end of 2007 and three year follow-up data should help clarify the 
differences between these two treatment options [1].   
4.1.3 Polyvinyl Alcohol Cryogels for Covered Stents 
Polyvinyl alcohol (PVA) cryogels represent a new material option for covered stents and 
a potential way to reduce complications from both restenosis and thrombosis.  Their 
ability to prevent restenosis is investigated in Part 2 and their ability to prevent 
thrombosis in Part 3 of this dissertation.  In Chapter 2, it was demonstrated that PVA 
cryogels have high ultimate stretch and may therefore be mechanically suitable for 
covered stents.  Since the membranes tested were no thicker than a stent strut, they 
should not add much bulk to the device – resulting in a low crimped profile and high 
deliverability.  Additionally, PVA cryogels can be used as a drug-delivery agent [15] to 
target drugs specifically to the lesion site if necessary.  Altogether, PVA cryogels may be 
able to resolve current covered stent problems – making this treatment option viable for 





4.2.1 PVA Solution Preparation & Covering of Stents 
Two PVA formulations were prepared at 15% and 20% by weight as described in 
Section 2.2.1; 10% PVA was not used as it was found to not fully coat stents.  
Concurrently, six balloon-expandable BMS made of 316L stainless steel (2 Express 
Biliary LD and 4 Palmaz Genesis on Opta Pro) were expanded to near their fully 
expanded diameter and removed from their catheter.  These two stent types were 
selected because they were easily obtained through a vascular surgeon collaborator.  
Stents were dip-coated with either the 15% or 20% PVA solution to make three covered 
stents of each PVA formulation.  Gravity caused excess PVA solution to flow out of the 
stent as seen in Figure 4.1.  Any excess PVA solution that did not flow out of the stent 
was removed manually with a guide wire in order to ensure that an even coat of PVA 
solution covered the entire stent and was no thicker than the stent struts which were 
approximately 100 µm thick.  Covered stents were then quickly placed into a cycling 
freezer for a total of eight freeze/thaw cycles in order to solidify the cryogel.  Upon 
completion of thermal cycling, the covered stents were placed into vials of deionized 
water in order to maintain the material hydrated until testing could begin.   
4.2.2 Crimping & Expanding of PVA Cryogel Covered Stents 
To begin, each covered stent was placed back onto its original balloon catheter and 
crimped down by hand.  The covered stent was then expanded by inflating the balloon to 
the manufacturer recommended value – between 8 and 10 atm.  Covered stent diameter 
was measured with a caliper before crimping, after crimping, and after expansion.  Once 
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expanded, each covered stent was visually inspected for tears in the PVA cryogel and 
separation of the PVA cryogel from the metal.   
 
 
Figure 4.1: Removing excess PVA solution from stent after dip-coating.  Gravity causes 
PVA solution to flow out of the stent – leaving behind a thin covering.  
 
4.2.3 Environmental Scanning Electron Microscope Imaging 
Images of two expanded covered stents were taken with an environmental scanning 
electron microscope (ESEM).  The Quanta 200 (FEI Corporation) was used with a 15 kV 
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accelerating voltage, beam spot size of 3, and a chamber pressure of 1 Torr.  In order to 
fit the covered stents into the ESEM chamber, a section of approximately 1 cm2 was cut 
with a small scissor and laid out nearly flat.  The interior of one Express stent and the 
exterior of one Palmaz Genesis stent (both covered with 20% PVA cryogel) were imaged 
at varying magnifications.   
4.3 Results 
Generally, coverage of stents with the PVA solution was good although on some stents 
there were a few cells on one or both ends that the PVA solution did not completely 
cover.  All membranes tolerated the crimping and expansion procedure well and Table 
4.1 shows the measured diameters after coating (coated diameter), after crimping 
(crimped diameter), and after expansion (expanded diameter) as well as the stretch 
ratios (crimped over coated, expanded over crimped, and expanded over coated) 
between the various states.  The Express Biliary LD covered stents had more metal and 
thus were more difficult to hand-crimp than the Palmaz Genesis covered stents; as a 
result, their crimped diameter is slightly larger.  Figure 4.2 shows a Palmaz Genesis 
covered stent crimped onto its balloon catheter before expansion.  The average stretch 
ratio from the crimped to expanded state was 1.32 for the Express and 1.78 for the 
Palmaz Genesis covered stents.  The average stretch ratio from the coated to the 























































































































































































































































































































































































Figure 4.2: Crimped PVA cryogel covered stent on balloon catheter prior to expansion. 
 
None of the membranes had visible tears after expansion, although there was some 
slight separation of the PVA cryogel membrane from the metal at the s-joints on two of 
the Palmaz Genesis covered stents.  No separation of the membrane from the metal 
was seen on the Express stents which did not have s-joints.  Additionally, there was no 
tearing or loss of coverage during expansion of the cells that were not completely 
covered during the coating process.  Photographs of an expanded Express and Palmaz 
Genesis stent are shown in Figure 4.3.   
ESEM images of expanded PVA cryogel covered stents can be seen in Figures 4.4 to 
4.8.  Excellent coverage of stent struts with the PVA cryogel material was found on all 
covered stents that were imaged.  When examining the interior (luminal) surface of the 
covered stents, it was difficult to locate stent struts beneath the PVA cryogel layer – 
indicating a smooth luminal surface which was completely covered with the PVA cryogel.  
On the exterior surface, stent struts were easily located and found to be entirely covered 
with the PVA cryogel.  Slight folding of the PVA cryogel layer was found adjacent to 
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some stent struts as shown in Figure 4.5.  No tears were found on the PVA cryogel 
material except at the sample edge where the covered stent had been purposely cut.   
The PVA cryogel formed an extremely thin coating of all metal struts which spanned the 
cells between struts.  In Figure 4.8, the PVA cryogel layer can be seen to be much 
thinner than the stent strut.  By measuring the thickness in pixels and comparing to the 
scale bar, the PVA cryogel layer is found to be approximately 10 µm thick.  Since the 
PVA cryogel membrane is thinner than the stent struts, it did not fill the entire volume 
created by neighboring struts.  The PVA cryogel formed a thin layer close to the luminal 







Figure 4.3: Close-up view of an expanded PVA cryogel covered Express (top) and 








Figure 4.4: ESEM image of the interior of an expanded PVA cryogel covered Express 
stent.  The PVA cryogel surface shown here does not appear to be porous and some 








Figure 4.5: ESEM image of the exterior of an expanded PVA cryogel covered Palmaz 
Genesis stent.  The PVA cryogel is seen here to cover the entire stent strut.  Slight 








Figure 4.6: ESEM image of the exterior of an expanded PVA cryogel covered Palmaz 
Genesis stent at the edge where the sample was cut to fit into the ESEM.  The cut edge 
of the PVA cryogel can be seen in the background while the foreground shows a 
















Figure 4.8: ESEM image of a Palmaz Genesis covered stent at the edge where it was 
cut.  The PVA cryogel covering can be seen pushed back – exposing the stent metal 






Figure 4.9: Diagram of PVA cryogel coverage of stent struts and cells. 
 
4.4 Discussion 
Vascular surgeons have begun using covered stents in a limited capacity recently as a 
treatment for atherosclerosis that could reduce restenosis rates when compared to BMS.  
Given the variability of clinical results, a greater diversity in available devices – 
especially materials – could lead to innovative new covered stents.  Since currently 
available covered stents typically have high thrombosis rates in small vessels [13], 
exploring new materials, such as PVA cryogels, could result in the development of a 
covered stent with reduced thrombotic complications.  Furthermore, if the material were 
mechanically suitable and able to form thin membranes, it could lead to a device with 
improved deliverability over existing covered stents. 
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These results demonstrate the feasibility of creating PVA cryogel covered stents, 
crimping them onto a balloon catheter for delivery, and expanding them to 
physiologically relevant diameters.  No major differences were noted between the 15% 
and 20% PVA cryogel covered stents during the coating, hand-crimping, and expansion 
processes.  By expanding the stents prior to coating with the PVA solution, the uniaxial 
tension curves in Figure 2.4 are essentially shifted to the right and a larger expanded 
diameter becomes possible.  While only balloon-expandable stents were tested here, 
PVA cryogels can be used to cover self-expanding stents as well.  In fact, self-expanding 
stents may be preferred because the multiple plastic deformations used in the covered 
stent fabrication process described here may induce unacceptable micro-fractures in the 
316L stainless steel.  This could reduce fatigue life, although no fracture issues were 
noticed in this study.  Since self-expanding stents are designed to flex, they could be 
coated with PVA solution at the expanded diameter and then crimped down for delivery.  
Another option for making balloon-expandable PVA cryogel covered stents is to coat the 
stents at the unexpanded diameter.  Although this fabrication method proved difficult 
with the hand-manufacturing techniques employed here, it should be possible with 
machinery.  Stents covered in this manner would require further testing to ensure that 
the PVA cryogel membrane is able to expand without tearing.  Future work should 
include refinements to the fabrication process of both self-expandable and balloon-
expandable stents.  These incremental improvements, e.g. machinery for the crimping 
procedure, will reduce the crimped profile beyond what was achieved here and improve 
device deliverability.   
Differences between the two stents investigated point towards several design issues that 
could improve reliability and deliverability.  The Express stents, which have no s-joints, 
had no separation of the PVA cryogel from the metal.  Because of this, it is suggested 
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that future PVA cryogel covered stents eliminate this type of feature.  Additionally, the 
Palmaz Genesis stents, which had fewer struts than the Express stents, could be 
crimped to a smaller diameter.  Therefore, a covered stent with fewer struts could have a 
decreased crimped profile and improved deliverability.  Further investigation of different 
stent designs will help elucidate other features to incorporate or eliminate in PVA cryogel 
covered stents.  It is likely that both self-expandable and balloon-expandable covered 
stents would be useful in different areas of the vasculature, as is the case with existing 
stents.  Since covered stents can block flow to vessels that branch off the stented 
segment, they would be best suited to vessels with minimal branching like the superficial 
femoral, femoropopliteal, and internal carotid arteries.  Additionally, PVA cryogel covered 
stents may be useful in the treatment of abdominal aortic aneurysms as a means of 
excluding the aneurysm and reinforcing the vessel wall. 
When examining the expanded stents visually and with ESEM, no major damage was 
found to the PVA cryogel membrane except for some separation at the s-joints.  ESEM 
images clearly showed an intact PVA cryogel membrane which completely covered stent 
struts.  The PVA cryogel layer, which was thinner than the stent strut, spanned stent 
cells closer to the luminal side – leaving a relatively smooth luminal surface where stent 
struts were difficult to locate with ESEM.  The coating of stent struts and resulting 
smooth luminal surface will likely help to reduce platelet adhesion as the presence of 
stent struts has been shown to increase platelet adhesion through alterations in blood 
flow [16]. 
In conclusion, these results demonstrate the feasibility of creating PVA cryogel covered 
stents which are capable of withstanding crimping and expansion processes without 
failing mechanically.  This represents a major step forward towards the creation of a new 
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class of covered stents which could reduce both restenosis and thrombosis rates when 
compared to other treatment options.  Since general feasibility of PVA cryogel covered 
stent fabrication has been demonstrated here, future work should focus on incremental 
changes to stent design which can further improve reliability and deliverability.    
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Part 1: Conclusions, Significance, and Future Directions 
 
The uniaxial tensile testing described in Chapter 2 demonstrated that polyvinyl alcohol 
(PVA) cryogel ring segments are capable of stretching to 300% of their original size – 
similar to how much a typical bare metal stent expands during deployment.  Ultimate 
stretch ratios of this magnitude are a necessary characteristic of a covered stent 
membrane in order to avoid mechanical failure during deployment.  While the ultimate 
stretch ratio of PVA cryogels was within the lower half of that of typical bare metal stents, 
PVA cryogels may not have to stretch that much if the stent is covered while in an 
already expanded state – a concept which was demonstrated in Chapter 4.  The ring 
segments tested were as thin as a stent strut and thus should not increase device profile 
greatly.  Additionally, because of the compliant nature of PVA cryogels, they may be 
able to reduce covered stent profile when compared to the relatively noncompliant 
materials polyester and polytetrafluoroethylene.   
Puncture testing results indicated a high push-through displacement for all PVA cryogel 
membranes which was not dependent on thickness within the range tested, but was 
higher for the larger probe diameter.  The high push-through displacement (larger than 
test mandrel radius) of PVA cryogel membranes is significant because it mitigates the 
safety concern of membrane puncture and potential embolization.  Since push-through 
displacement did not depend on membrane thickness within the range tested, thin 
membranes (110 µm) could be used to make covered stents with high deliverability and 
no loss of puncture resistance.   
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The ability to make PVA cryogel covered stents by hand, crimp them onto balloon 
catheters, and expand them represents a major milestone in the development of these 
devices.  While there was some minor variability between covered stents due to the 
hand manufacturing, visual inspection and environmental scanning electron microscope 
imaging showed smooth PVA cryogel surfaces and complete coverage of stent metal 
without tears.  While the stent metal did not fracture here, multiple plastic deformations 
of stainless steel stents could induce micro-fractures and reduce fatigue life.  In order to 
avoid this potential issue, balloon-expandable stents could be coated with PVA solution 
at the unexpanded diameter.  Alternatively, self-expanding stents could be covered with 
PVA solution at the expanded diameter and crimped down for delivery – similar to how 
they are currently produced.  Future PVA cryogel covered stents should be designed 
similar to the Viabahn Endoprosthesis to minimize the number of struts and geometry 
like s-joints where the PVA cryogel tended to separate from the metal.  Future work 
should include refinements to the fabrication process including control of the PVA 
cryogel membrane thickness, quality control to ensure complete coverage of all stent 
cells, and improvement of the crimping procedure to achieve the smallest crimped profile 
possible. 
Altogether, PVA cryogels performed well in the various mechanical tests – meeting the 
design requirements of high ultimate stretch and puncture resistance – and appear to be 
suitable for covered stents.  Manufacturing feasibility was demonstrated by making, 
crimping down, and expanding PVA cryogel covered stents successfully without 
damaging the membrane.  PVA cryogels represent a new material choice for covered 
stents and could be the key to reducing complications from both restenosis and 
thrombosis in the future, especially in vessels without extensive branching like the 





PART 2:  





Finite Element Analysis of Tissue Prolapse in Stent Cells 
 
6.1 Background 
6.1.1 Finite Element Analysis of Stents & Arteries 
Finite element analysis (FEA) is a powerful computational tool which can be used to 
analyze a number of biomechanical problems and has been employed extensively in the 
study of stents and arteries.  One important study has shown a link between elevated 
arterial wall stress (calculated by FEA) and clinical restenosis rates [1].  In the study, two 
different stents (Medtronic’s S7 and Boston Scientific’s NIR) were analyzed to determine 
the stress that they induce on the vessel wall.  The investigators found that the NIR stent 
induced stresses above 4 MPa in a larger volume of tissue than the S7.  Clinically, the 
NIR stent has a six-month restenosis rate of 19% while the S7 stent had a six-month 
restenosis rate of 10.1% [2, 3].  While this FEA study does not provide conclusive 
evidence that higher artery stresses cause higher restenosis rates, it does provide some 
evidence and illustrates the utility of FEA in evaluating stent designs.  Other 
investigations have focused on the stent alone and studied the effect of stent geometry 
on various mechanical parameters like stent recoil, longitudinal shortening, and balloon 
deployment pressure [4, 5].  These kinds of studies can be helpful for stent 
manufacturers as they create new stent designs.  More complicated models have been 
developed which include contact between the stent, artery, and plaque [6].  One recent 
study combined FEA with an optimization algorithm to determine how geometrical 
parameters affect the competing mechanical concerns of wall stress, lumen gain, and 
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cyclic deflection [7].  While not directly clinically relevant, studies like this one could 
eventually lead to lesion-specific or patient-specific stenting by understanding the 
competing mechanical factors involved in these procedures. 
6.1.2 Tissue Prolapse & Covered Stents 
Tissue prolapse is a common event during stenting wherein the tissue between stent 
struts deflects inward towards the lumen.  Prolapse is detectable by intravascular 
ultrasound, and occurs from 20% to 40% of the time, reducing lumen diameter by up to 
20% [8, 9].  Two separate studies have recently used FEA to study the effects of stent 
cell geometry on tissue prolapse and arterial stress [10, 11].  Both studies found tissue 
prolapse and arterial wall stress to depend on stent cell geometry and recommended 
FEA as a tool to investigate future stent designs.   
Covered stents have not been modeled with FEA as extensively as bare stents, although 
one recent study has used FEA to examine the expansion of silicone covered 
microstents [12].  The authors found that expansion pressure, elastic recoil, and 
longitudinal shortening all increased for the covered microstents when compared to bare 
microstents.  Since covered stents span the area between stent struts with a membrane 
material, they will likely influence both tissue prolapse and arterial wall stress.  To the 
author’s knowledge, no study has been carried out which aims to quantify tissue 




6.2.1 Stent Cell Geometry  
Two common stent cell geometries were chosen for this analysis: the “diamond” and the 
“w” shapes which are present in the Palmaz Genesis and Express stents shown in 
Chapter 4.  To create the geometries, each shape was drawn on a flat plane and 
projected onto a cylinder that was either 3.5 mm or 7.4 mm in diameter using 
SolidWorks 2009 (Dassault Systèmes) in order to represent either a coronary or an iliac 
artery [11, 13].  The wall thicknesses were set at 0.5 mm for the coronary artery [11] and 
1.3 mm for the iliac artery [13].  Each part file was exported to ProEngineer Wildfire 4.0 
(Parametric Technology Corporation) where it was then converted to the IGES file 
format.  Direct conversion to the IGES file format within SolidWorks was not done 
because of a compatibility issue that arose with the FEA software.   
6.2.2 Material Models 
Arterial tissue is assumed to be incompressible, isotropic, homogeneous, and elastic 
[11].  It was modeled with a reduced form of the generalized Mooney-Rivlin model given 
by 
( ) ( ) ( ) ( )( ) ( )313021112120201110 333333 −+−−+−+−+−= IaIIaIaIaIaWartery . (6.1) 
I1 and I2 are the first and second strain invariants given by Equation 6.2 and Equation 6.3 
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Values for the model coefficients a10 to a30 are taken from a previous study of uniaxial 
and biaxial testing of human femoral arterial tissue and are shown in Table 6.1 [11].   
Polyvinyl alcohol (PVA) cryogels are assumed to be incompressible, isotropic, 
homogeneous, and elastic [14].  A 20% PVA formulation was chosen as it was 
determined to be a likely formulation for a covered stent in Chapter 4.  This material was 
also modeled with the Mooney-Rivlin model (Equation 6.1).  Values for the model 
coefficients, see Table 6.1, for a 20% PVA cryogel model were calculated in ANSYS 
12.0 (ANSYS, Inc.) with a linear regression algorithm based on the uniaxial test data of 
PVA cryogel ring segments at 0.1 mm/s in Chapter 2.  Figure 6.1 shows the generated 
20% PVA cryogel model with the corresponding experimental data. 
 
Table 6.1: Mooney-Rivlin model coefficients (kPa). 
 Artery [11] 20% PVA Cryogel 
a10 18.90 -101.28 
a01 2.75 107.15 
a20 590.42 46.183 
a11 857.18 -205.15 





Figure 6.1: Stress-strain plot of 20% PVA cryogel material model shown with test data 
from Chapter 2. 
 
6.2.3 Finite Element Analysis Parameters 
Tissue prolapse is analyzed by modeling the vascular tissue contained within the stent 
repeating unit using ANSYS 12.0.  Following the method developed by Prendergast et 
al. [11], an external pressure of 450 mmHg, the maximum in vivo pressure a stent is 
expected to experience, is applied to the arterial tissue.  The sides of the tissue are 
rigidly constrained where the stent struts would be in contact with the artery wall and the 
luminal surface is left unconstrained.  Tetrahedral SOLID285 elements (4 node, mixed u-
P) were chosen for the analysis because they work well with geometries produced by 
CAD packages and are capable of handling the Mooney-Rivlin material model.  Meshed 
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volumes of both the diamond- and w-shape can be seen in Figure 6.2.  The diamond-
shape has been reduced to a quarter model and the w-shape has been cut in half 
because of symmetry.   
 
 
Figure 6.2: Arterial tissue mesh of diamond (left) and w (right) shape.  The mesh has 
been made denser at areas of high stress.  The ‘L’ illustrates the location of the luminal 
side. 
 
Mesh convergence analyses were completed for all four cases to determine the 
sufficient mesh density.  For mesh convergence, maximum displacement and maximum 
midline perimeter stress were monitored as the mesh was made finer.  Maximum midline 
stress was chosen as a stable measure of stress and was measured around the 
perimeter of the shape as seen in Figure 6.3.  Once a mesh density was selected, a 
20% PVA cryogel layer was added on the luminal side of the artery that was either 100 
µm or 200 µm thick.  Neither the size nor the shape of the arterial tissue was altered, 
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only an extra layer was added to the luminal side as shown in Figure 6.3.  Contact 
between the two materials was modeled by having nodes on the area where the two 
materials met shared by elements on either side of the boundary such that their 
displacements were matched.  The maximum and average stress of a plane at the 
midline of the artery (surface contained within the perimeter shown in Figure 6.3) as well 
as maximum prolapse (radial displacement) of arterial lumen nodes are reported as a 





Figure 6.3: Diagram showing different material models for elements which represent 
artery (purple) and 20% PVA cryogel (green) for diamond (left) and w (right) shape.  The 
white line marks the path along which the midline perimeter stress was taken for mesh 




Mesh convergence results for the small and large diameter diamond-shapes can be 
seen in Figures 6.4 and 6.5.  The chosen mesh density had less than 5% difference in 
maximum displacement and maximum midline perimeter stress between itself and the 






Figure 6.4: Mesh convergence for small diameter diamond-shape.  Mesh density 




Figure 6.5: Mesh convergence for large diameter diamond-shape.  Mesh density 





Mesh convergence results for the small and large diameter w-shapes can be seen in 
Figures 6.6 and 6.7.  For the small diameter w-shape, there was less than a 5% 
difference between the finest mesh and the chosen mesh density for maximum 
displacement and maximum midline perimeter stress.  For the large diameter w-shape, 
there was less than a 5% difference between the finest mesh and the chosen mesh 





Figure 6.6: Mesh convergence for small diameter w-shape.  Mesh density increases to 




Figure 6.7: Mesh convergence for large diameter w-shape.  Mesh density increases to 
the right.  Circle is chosen mesh density. 
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Maximum midline stress, average midline stress, and maximum prolapse for each of the 
four cases are reported in Tables 6.2 to 6.5 and can be seen in Figures 6.8 to 6.19.  
Maximum prolapse, δ, is the radial displacement of the nodes on the luminal arterial 
surface and was calculated by 
22
yx UU +=δ         (6.4) 
where Ux and Uy are the displacements in the x- and y-direction, respectively.  Prolapse 
was greater in the smaller diameter vessels for both shapes.  The diamond-shape 
elicited more prolapse than the w-shape at both vessel diameters.  Overall, the stent 
covering caused a reduction in prolapse.  The reductions in prolapse were greater for 
the smaller diameter vessels than for the larger diameter vessels.  The small diameter 
diamond-shape had the largest percent reduction in prolapse of 13% with the addition of 
a 200 µm thick PVA cryogel layer.  Reductions in prolapse caused by the addition of a 
PVA cryogel layer strongly correlated with prolapse in the uncovered state for both the 
100 µm (r=0.964, p=0.036) and the 200 µm (r=0.981, p=0.019) thick PVA cryogel layer.   
Maximum and average midline stresses were higher in the smaller diameter vessel for 
both shapes.  When comparing stent shapes, maximum midline stress was higher for 
the w-shape while the average midline stress was higher for the diamond-shape.  The 
stent covering reduced the stress values in the midline of the artery wall.  Furthermore, 
the thicker the covering, the more the stress was reduced.  Overall, stresses were 
reduced by a larger percent than prolapse.  The small diameter diamond-shape had the 
largest percent reduction in stress with a 29% reduction of the maximum midline stress 
and a 23% reduction in average midline stress when a 200 µm thick PVA cryogel layer 
70 
 
was added.  Reductions in maximum midline stress caused by the 100 µm thick PVA 
cryogel layer strongly correlated with the maximum midline stress caused by the 
uncovered stent (r=0.968, p=0.032).  Reductions in average midline stress caused by 
the 200 µm thick PVA cryogel layer strongly correlated with the average midline stress 




Table 6.2: Prolapse and midline stress for small diameter diamond-shape. 
PVA Cryogel Thickness (µm) 0 100 200 
Maximum Prolapse (mm) 0.241 0.228 0.210 
Maximum Midline Stress (kPa) 153.86 133.73 108.61 




Table 6.3: Prolapse and midline stress for large diameter diamond-shape. 
PVA Cryogel Thickness (µm) 0 100 200 
Maximum Prolapse (mm) 0.138 0.138 0.138 
Maximum Midline Stress (kPa) 57.50 55.58 53.08 




Table 6.4: Prolapse and midline stress for small diameter w-shape. 
PVA Cryogel Thickness (µm) 0 100 200 
Maximum Prolapse (mm) 0.182 0.178 0.171 
Maximum Midline Stress (kPa) 250.52 225.41 218.07 




Table 6.5: Prolapse and midline stress for large diameter w-shape. 
PVA Cryogel Thickness (µm) 0 100 200 
Maximum Prolapse (mm) 0.117 0.117 0.116 
Maximum Midline Stress (kPa) 127.98 119.84 116.97 





Figure 6.8: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.9: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.10: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.11: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.12: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.13: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.14: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.15: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.16: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.17: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.18: Displacement with undeformed edge (top) and midline stress (bottom) for 





Figure 6.19: Displacement with undeformed edge (top) and midline stress (bottom) for 






FEA was used to analyze the effects of stent cell geometry, vessel diameter, and 
covered stent membrane thickness on tissue prolapse and arterial wall stress.  Generally 
speaking, the addition of a PVA cryogel layer does reduce both prolapse and arterial 
wall stress, although the amount the stress or prolapse was reduced varied greatly 
among the four cases investigated.  The covered stent membrane reduced tissue 
prolapse by a maximum of 13%, maximum midline artery stress by a maximum of 29%, 
and average midline artery stress by a maximum of 23%.  The greater the initial stress 
or prolapse, the greater was the reduction by adding the PVA cryogel layer.  Whether or 
not these reductions in prolapse and artery wall stress would cause a clinically 
measurable change in restenosis rate would need to be validated by a clinical trial. 
Of note is that the artery wall stress was higher in both smaller diameter vessels when 
compared to the larger diameter vessels.  As previously mentioned, one FEA study of 
two stents demonstrated higher artery wall stress in a stent which had a higher clinical 
restenosis rate[1].  The results here confirm that idea by showing higher artery wall 
stress in smaller vessels which have been shown to restenose at a higher rate when the 
same stent design is deployed in different size vessels [15].  Previous studies of 
prolapse in uncovered stents have found radial deflections between 0.11 mm and 0.48 
mm [10, 11].  The results here are within that range, although slightly different 
techniques were used.  Artery wall stress results were also found to be similar in 
magnitude to other previous investigations of uncovered stent expansion [7, 11]. 
This study is limited in that it does not model the expansion of the stent and its contact 
with the vessel wall; the stent was assumed to be already expanded and in contact with 
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the artery.  The stent was assumed to be rigid and did not deflect under the applied 
extraluminal pressure, although it is possible that an elastic stent might deflect under 
these conditions [11].  Additionally, the vessel wall was assumed to be isotropic and 
homogenous when it is in fact composed of an intima, media, and adventitia [13].  This 
simplifying assumption, however, is made often in FEA analyses of stented arteries and 
is expected to be reasonable because the load is carried mostly by the media [7, 11].   
In conclusion, the PVA cryogel layer was found to reduce both prolapse and artery wall 
stress, although the actual reduction varied depending on the artery shape and 
diameter.  Reducing artery wall stress is of interest because it could reduce the clinical 
restenosis rate, although it is not known if the reductions caused by the PVA cryogel 
layer shown here are large enough to cause such a change. 
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Prevention of Smooth Muscle Cell Migration With Polyvinyl Alcohol Cryogels 
 
7.1 Background 
7.1.1 Restenosis Biology 
Angiographic restenosis has been defined clinically as an obstruction of 50% or greater 
by diameter stenosis [1].  While this definition of restenosis is binary and does not give 
information on the severity of the stenosis, it is important because coronary flow reserve 
becomes reduced for diameter stenoses greater than 50% [2, 3].  Stents today have 
restenosis rates of 20% to 45% which depend on risk factors such as diabetes, number 
of stents implanted, and stent length among others [4-9].  Restenosis can be separated 
into three unique processes: elastic recoil, negative remodeling, and intimal hyperplasia 
[2, 10].  Elastic recoil and negative remodeling are generally associated with balloon 
angioplasty whereas neointimal hyperplasia is generally associated with in-stent 
restenosis [2].  However, all three processes can contribute to restenosis after balloon 
angioplasty [10]. 
Elastic recoil is an immediate mechanical response after balloon angioplasty.  Within a 
few minutes of balloon deflation, the artery recoils similar to a rubber band after being 
stretched; this can lead to a loss in cross sectional area of up to 50% [11].  Negative 
remodeling is a change in arterial size after vascular injury [12].  This process is initiated 
by the conversion of adventitial fibroblasts to myofibroblasts (by inflammatory cells) 
which then secrete extracellular matrix, causing vessel constriction and the formation of 
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a fibrotic scar at the injury site [13].  This process can be observed approximately 1 to 6 
months after an angioplasty procedure [10].  Neointimal hyperplasia is the process by 
which the intimal layer of the artery thickens.  Medial vascular smooth muscle cells 
(SMC) migrate to the intima and begin to proliferate and secrete large amounts of 
extracellular material – reducing the luminal diameter [14, 15]. 
7.1.2 Stents & Neointimal Hyperplasia 
Bare metal stents (BMS) are metal scaffolds that are delivered to the lesion site via 
catheter where they are expanded either by balloon- or self-expansion.  While BMS have 
been able to eliminate the deleterious effects of elastic recoil and negative remodeling, 
they increase the level of neointimal hyperplasia when compared to angioplasty alone.  
However, the initial gain in lumen diameter is so much greater with stents that it 
outweighs the late lumen loss of neointimal hyperplasia and gives lower overall 
restenosis rates [2, 10, 16].   
Injury from balloon angioplasty can cause dissection through the tunica media and 
exposure of the external elastic lamina [17, 18].  The endothelial denudation causes the 
loss of normally present anti-thrombotic factors such as nitric oxide, prostaglandin, and 
tissue plasminogen activator promoting platelet adhesion and aggregation [10].  
Platelets bound to fibrin release cytokines such as platelet-derived growth factor 
(PDGF), thromboxane A2, and adenosine diphosphate which signal further platelet 
aggregation and thrombus formation.  PDGF and epidermal growth factor released by 
the platelets serve as mitogens and chemotaxis agents for vascular SMC and 
macrophages.  The vascular SMC, which normally lay in a quiescent phase in the 
media, then migrate to the site of injury in the intima and begin to proliferate and produce 
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extracellular material [10, 18, 19].  The composition of intimal hyperplasia regions is 
quite different from that of atherosclerotic plaques.  While an atheroma tends to be 
mostly acellular and contain cholesterol, necrotic regions, macrophages, and possibly 
calcium deposits, the thickened intima contains mostly vascular SMC which produce 
large amounts of extracellular matrix [20].   
BMS provide no barrier to vascular SMC migration and cells pass directly through the 
area between stent struts forming a thick neointima that can completely envelop stent 
struts [21].  Drug-eluting stents (DES) are BMS coated with a polymer which allows the 
passive diffusion of an anti-neoplastic drug, e.g. paclitaxel or sirolimus, across the stent 
surface [2, 10, 22] to prevent cellular proliferation and eliminate neointimal hyperplasia.  
DES have had particular success in the coronary arteries, reducing restenosis rates by a 
relative 50% to 80% [2], although concerns over late stent thrombosis (beyond the first 
year of implantation) are growing as more long term data on DES become available.  
One recent meta-analysis of 14 contemporary clinical trials of coronary stenting noted 
that DES carry a four to five fold increased risk of late stent thrombosis over BMS [23].  
As an alternative to the prevention of neointimal hyperplasia by DES, vascular SMC 
migration could be blocked by the physical barrier of a covered stent membrane. 
7.1.3 Types of Migration Assays  
Two common in vitro methods for measuring cellular migration include the wound assay 
and the modified Boyden chamber assay [24].  In the wound assay, cells are grown to 
confluence in a dish and then a wound is created by scratching the surface with a cell 
scraper or similar device.  The cell migration across the surface can then be monitored 
by taking microscopic images at regular intervals until the cells have filled the wound [24, 
90 
 
25].  Modified Boyden chambers consist of an upper and a lower chamber which are 
separated by a thin, porous filter as shown in Figure 7.1.  Cells suspended in media are 
loaded in the upper chamber while the lower chamber contains media and a 
chemoattractant.  The cells are allowed to migrate towards the chemoattractant for a 
fixed incubation period.  Afterwards, the filters are fixed and stained and the cells that 
migrated to the bottom of the filter are counted under magnification [24, 26, 27].  Since 
the cellular migration in intimal hyperplasia is perpendicular to a surface (through stent 







Figure 7.1: Modified Boyden chamber layout.  Upper chamber contains media and cells 
in suspension.  Lower chamber contains a chemoattractant and is separated from the 




7.2.1 Cell Isolation & Culture 
Porcine aortic SMC were isolated from tissue donated by a local abattoir following a 
protocol similar to Butcher et al. [28].  Aortas were removed from farm pigs shortly after 
sacrifice.  The aortas were then rinsed in Hank’s Buffered Saline Solution and incubated 
in a 5X antibiotic/antimycotic solution for one hour.  Endothelial cells were removed by 
using a collagenase digestion combined with a gentle scraping method.  To isolate SMC, 
the aortic tissue was cut into small pieces with sterile scissors.  The pieces were then 
shaken in T75 flasks with 300 U/mL collagenase type 2 in Dulbecco's Modified Eagle 
Medium (DMEM) for four hours.  The cell and tissue liquid was subsequently filtered and 
spun down in a centrifuge.  The cells were then counted and plated at a density of 3,500 
cells/cm2.   
Growth media was prepared with 500 mL DMEM (Cellgro); 50 mL fetal bovine serum 
(FBS) (Cellgro); 5 mL L-glutamine (Cellgro); 5 mL penicillin-streptomycin solution 
(Cellgro); and 2.9789 g HEPES buffer (Cellgro).  HEPES buffer (unsterile) was added to 
the DMEM to give a concentration of 25 mM and passed through a 0.22 µm sterile filter; 
the FBS, L-glutamine, and penicillin-streptomycin were then added.  Cells were cultured 
in T75 culture flasks (Corning) with growth media that was replaced every third day until 
they reached approximately 80% confluency in a cell culture incubator at 37°C and 5% 
CO2.  To passage cells, the growth media was aspirated and the cells were rinsed with 
Dulbecco’s phosphate buffered saline (DPBS) (Cellgro).  Once the DPBS was aspirated, 
3 mL of 0.05% trypsin (Invitrogen) was added and the cells were incubated for 
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approximately five minutes until the detached cells could be seen in the flask.  Six 
milliliters of growth media was then added to inactivate the trypsin.   
To count the cells, 50 µL of the cell suspension was added to 20 mL DPBS and counted 
with a Multisizer II (Beckman Coulter).  Size limits for SMC were set between 8 µm and 
30 µm and each sample was run twice in order to take an average reading.  The number 
of cells in a suspension was determined by  
8029
2
SumResult Coulter )(# ⋅⋅= mLCell
      (7.1)
 
where Coulter Result Sum is the sum of both readings and 802 is a dilution factor based 
on the volume of the cell suspension and DPBS.  The cell suspension was then spun 
down in a centrifuge, the trypsin/media aspirated, and an appropriate amount of media 
was added to obtain the desired cell concentration.   
7.2.2 Modified Boyden Chamber Preparation 
The modified Boyden chambers (BD), inserts, used in this study had 8 µm pores and 
were either covered or uncovered with a polyvinyl alcohol (PVA) cryogel.  The pore size 
was chosen based on previous studies of SMC migration in modified Boyden chambers 
[27, 29].  To make the covered inserts, two formulations of PVA were prepared at 10% 
and 20% by weight by adding PVA powder to deionized water per Equation 2.1.  These 
formulations were chosen to represent a low and high percent weight PVA that might be 
used in covered stents.  The PVA-water mixture was heated in an autoclave at 120°C in 
order to dissolve the PVA and sterilize the resulting solution.  After sterilization, the 
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mixture was moved to the biosafety hood and mixed manually to ensure an even 
consistency.  At the same time, individual inserts were placed right side up and PVA 
solution was poured into the upper chamber so as to completely coat the porous 
membrane.  The inserts were then inverted and excess PVA solution was removed.  The 
covered inserts were placed into sterile containers and put into an incubator for three 
freeze-thaw cycles.  After thermal cycling, the covered inserts were placed into sterile 
containers with deionized water until testing.  Uncovered inserts also underwent thermal 
cycling to ensure that it was not a source of differences between the groups.   
Since thickness of the porous membrane was not available from the manufacturer, 
precise measurements of the PVA cryogel covering thickness were not taken.  However, 
to give an approximation, the PVA cryogel covering from one 20% PVA cryogel insert 
was removed after testing.  A section of the covering was cut and imaged next to a 
reference object of known size.  The number of pixels was then measured and 
compared with the reference object in order to give a thickness measurement using 
GNU Image Manipulation Program (GNU Project).   
It is expected that a covered stent membrane would become covered with fibronectin or 
other proteins after implantation [30].  Therefore, some inserts were coated with human 
fibronectin (BD) in order to more closely match the in vivo situation.  Fibronectin 
solutions were prepared at 5, 10, or 20 µg/mL by resuspending fibronectin in sterile 
deionized water and then making further dilutions with DPBS per manufacturer 
recommendations.  This concentration range was chosen based on previous 
investigations of cellular migration with fibronectin coated inserts [27, 31].  Inserts were 
coated by placing 700 µL of the fibronectin solution into the lower chamber and 200 µL 
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into the upper chamber.  Inserts were left overnight at 20°C and then rinsed with DPBS 
before beginning a migration experiment. 
7.2.3 Migration Assay Protocol 
All SMC used in migration assays were between passage number 7 and 10.  After 
counting the cells and spinning them down, they were resuspended in DMEM with 1% 
bovine serum albumin (BSA) to give a concentration of 50,000 cells per 300 µL.  This 
media was prepared by taking 100 mL of DMEM (with HEPES), dissolving 1 g BSA 
(Fisher Scientific), and then passing it through another 0.22 µm filter.  One milliliter L-
glutamine and 1 mL penicillin-streptomycin were added, but no FBS.   
The lower chamber was filled with 800 µL growth media (DMEM + 10% FBS) while the 
upper chamber contained the cells resuspended in DMEM + 1% BSA so that the cells 
would be attracted to the higher level of serum and migrate towards the lower chamber.  
Three hundred microliters of media with resuspended cells (50,000) were placed in the 
upper chamber and the chambers were incubated for 24 h.  Three sets of migration 
experiments were completed.  
a) Uncovered inserts vs. PVA cryogel covered inserts without fibronectin coating 
b) Fibronectin pilot study of uncovered inserts  
c) Uncovered inserts vs. PVA cryogel covered inserts with fibronectin coating 
In experiment (a), three groups were evaluated: uncovered inserts, 10% PVA cryogel 
covered inserts, and 20% PVA cryogel covered inserts.  Six inserts were used in each 
group for a total of 18.  In experiment (b), three fibronectin concentrations were 
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evaluated: 5, 10, and 20 µg/mL in uncovered inserts.  As this was a pilot study, only one 
insert in each group (total of three) were used.  Experiment (c) was identical to 
experiment (a) except that the inserts were coated with 10 µg/mL fibronectin 
(concentration determined from pilot study (b)).  Four inserts were used in each group 
for a total of 12. 
7.2.4 Histology & Migrated Cell Counting  
After 24 h migration, inserts were removed from the well plate and the upper surface 
was wiped with a cotton swab to remove any adherent cells that had not migrated to the 
lower surface.  Removing cells from the upper surface is necessary in order to avoid 
accidentally counting them as migrated cells.  A HemaColor Stain Set (EMD Chemicals) 
was used to fix and stain the inserts by progressively placing each insert into methanol 
fixative, eosin stain, methylene blue stain, and three rinses of deionized water for two 
minutes each.  After drying, inserts were visualized with an Eclipse TE2000-U inverted 
microscope (Nikon) with a 20X objective.  Three digital images were taken at different 
locations on each insert.  Cells were counted manually using ImageJ software (National 
Institutes of Health) and are reported as the average number of migrated cells per high 




7.3.1 Experiment (a): Uncovered Inserts vs. PVA Cryogel Covered Inserts Without 
Fibronectin Coating 
The thickness of one PVA cryogel membrane was determined to be 170 µm – 
approximately the size of a stent strut.  PVA cryogel covered inserts (10% and 20% 
formulations) had a significantly reduced amount of migrated cells per high power field 
when compared to uncovered inserts, p<0.05.  Migration in the positive control was 
modest with an average of 5.6 cells per high power field, see Figure 7.2.  Sample 
pictures of migrated cells are shown in Figure 7.3.  The 10% PVA formulation had zero 
migrated cells and the 20% formulation had an average of 0.2 cells per high power field.  
There was no statistically significant difference in migrated cells between the two PVA 





Figure 7.2: Average migrated cells per high power field without fibronectin coating.  
Error bars represent one standard deviation.  Each group represents 6 inserts and 3 

































































































































































7.3.2 Experiment (b): Fibronectin Pilot Study of Uncovered Inserts 
Fibronectin coating increased SMC migration at all concentrations.  The 10 µg/mL 
concentration had the highest amount of migrated cells, see Figure 7.4, and was thus 
chosen for Experiment (c) so as to provide the most migration possible.  Sample pictures 
of migrated cells are shown in Figure 7.5.  There was no statistically significant 





Figure 7.4: Average migrated cells per high power field on uncovered inserts with 






























































































7.3.3 Experiment (c): Uncovered Inserts vs. PVA Cryogel Covered Inserts With 
Fibronectin Coating 
Fibronectin coated uncovered inserts had a larger number of migrated cells than 
uncoated uncovered inserts from Experiment (a), see Figure 7.6.  Sample pictures of 
migrated cells are shown in Figure 7.7.  Migration through PVA cryogel covered inserts 
was unchanged with fibronectin coating; the 10% formulation had zero migrated cells 
and the 20% formulation had 0.42 migrated cells per high power field.  The difference 
between uncovered and PVA cryogel covered inserts was significant (p<0.05), although 
there was no statistically significant difference between the two PVA formulations.   
 
 
Figure 7.6: Average migrated cells per high power field with 10 µg/mL fibronectin 
coating.  Error bars represent one standard deviation.  Each group represents 4 inserts 






















































































































PVA cryogel coverings were shown to eliminate virtually all SMC migration in the 
absence and presence of fibronectin.  There was no statistical difference in number of 
migrated cells between the two PVA cryogel formulations in any experiment.  The 10% 
formulation completely stopped migration while there was a small number of migrated 
cells seen with the 20% formulation.  This result is contrary to expectations as thickness 
was anticipated to be higher and porosity lower in the higher percent weight cryogel [32].  
One possible explanation for this behavior lies in the fact that the 20% PVA solution is 
more viscous than the 10% once the PVA is dissolved into the water.  Tiny air bubbles, 
trapped within a more viscous solution, would be less likely to flow out of the insert and 
may become stuck.  If those bubbles were to later pop, e.g. during thermal cycling, they 
would leave the original surface exposed and cells would be able to migrate through the 
8 µm pores uninhibited.   
The thickness of one PVA cryogel covering was determined to be 170 µm – 
approximately the size of a stent strut [33].  While this measurement was only taken of 
one insert, all inserts had similar thicknesses based on visual inspection.  Although the 
PVA cryogel covered stents made in Chapter 4 had thinner membranes, SMC migration 
is not expected to be different with covered stents because the pore size of PVA 
cryogels is less than 1 µm [32] – much smaller than SMC (8 µm to 30 µm).  Further 
experiments including in vivo studies, e.g. pig or rabbit, of in-stent restenosis are 
recommended to validate the present results. 
One limitation of the current study is that in-stent restenosis occurs on a time scale of 
months and these experiments were all completed in 24 hours.  In-stent restenosis is 
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typically studied in animal models and few in vitro models for studying restenosis exist 
[34].  However, the cellular migration in modified Boyden chambers is analogous to the 
SMC migration seen during neointimal hyperplasia.  Furthermore, a strong correlation 
has been shown between a tumor cell’s invasive potential in vivo and its ability to invade 
in vitro in the modified Boyden chamber [35].  Because of this, the modified Boyden 
chamber is expected to be a reasonable in vitro model of the cellular migration seen 
during neointimal hyperplasia.  However, in several studies of in-stent restenosis in 
covered stents, neointimal hyperplasia has been seen to grow inward from the edges 
[36, 37].  This type of cellular ingrowth, termed the candy wrapper effect because of its 
angiographic appearance, may be related to procedural differences during implantation 
[38].  Since this type of migration is not simulated well by the modified Boyden chamber 
assay, it should be evaluated in vivo. 
In conclusion, both the low and high percent weight PVA cryogel formulations were 
shown to significantly reduce SMC migration in an in vitro model of cellular migration.  
This result demonstrates that PVA cryogels have the potential to reduce in-stent 
restenosis by preventing SMC migration.  Future work should include animal testing of 
PVA cryogel covered stents to determine if they are able to prevent in-stent restenosis in 
vivo. 
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Part 2: Conclusions, Significance, and Future Directions 
 
Finite element analysis (FEA) was employed to investigate tissue prolapse and artery 
wall stress for two different stent cell geometries (diamond- and w-shape) and two 
different vessel diameters (3.5 mm coronary and 7.4 mm iliac) with uncovered and PVA 
cryogel covered stents.  The addition of a PVA cryogel layer was found to reduce tissue 
prolapse by up to 13% and maximum midline artery stress by up to 29%.  The amount 
that the prolapse or artery wall stress was reduced depended on the vessel diameter 
and stent cell geometry.  Furthermore, the greater the prolapse or artery wall stress 
caused by the uncovered stent, the greater was the reduction in prolapse or artery wall 
stress caused by the PVA cryogel covering.  Also of note was that higher stresses were 
found in smaller vessels with the same stent cell geometry.  These higher stresses may 
be indicative of a higher likelihood for restenosis as at least one other study has shown a 
link between high artery wall stresses and restenosis.  Generally, reducing tissue 
prolapse and artery wall stress may help reduce clinical restenosis rates, but it is 
unknown at this point if the reductions seen in this study will lead to clinically 
measureable improvements. 
Future FEA work might seek to increase model sophistication by incorporating 
interactions between the artery, plaque, stent, and PVA cryogel in order to more 
precisely determine the biomechanical benefits of PVA cryogel covered stents – 
especially if more flexible self-expanding stents are to be used.  Additionally, it may be 
interesting to model the expansion of a PVA cryogel covered stent versus an equivalent 
uncovered stent without any artery interactions to see if there are major differences in 
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balloon inflation pressure, elastic recoil, and longitudinal shortening between the two 
stent types.  Together, these two types of simulations could guide PVA cryogel covered 
stent design in order to create a reliable device capable of reducing both tissue prolapse 
and artery wall stress. 
Migration through a modified Boyden chamber was used as a model for the cellular 
migration between stent struts seen during the process of in-stent restenosis.  The 
results of this study indicate that PVA cryogel membranes (approximately 170 µm thick) 
are capable of stopping smooth muscle cell migration in vitro in both the absence and 
presence of fibronectin – suggesting that the same effect would be seen in vivo.  Future 
work should include animal or human trials of restenosis that compare uncovered and 
PVA cryogel covered stents to determine if PVA cryogel covered stents are able to 














PART 3:  





In Vitro Biomaterial Thrombogenicity Testing 
 
9.1 Background 
9.1.1 In-Stent Thrombosis & Blood Contacting Biomaterials 
In-stent thrombosis is the process of clot formation within the stented region of a vessel.  
Angioplasty and stenting damage the vessel wall and expose the thrombotic 
components (von Willebrand factor, collagen, fibronectin, and tissue factor) below the 
endothelial layer [1-4].  Platelets then adhere and aggregate to form a thrombus which 
can completely occlude the vessel.  Fortunately, the combined practices of high balloon 
inflation pressure to ensure proper stent apposition and dual anti-platelet therapy, i.e. 
aspirin and ticlopidine, have reduced the risk of bare metal stent (BMS) thrombosis to 
less than 1% to 2% at one month [5].  Recently however, late stent thrombosis has 
become a concern for drug-eluting stents (DES) [6].  One recent 9-month study of 
paclitaxel- and sirolimus-eluting stents found that there was a 45% mortality rate 
associated with stent thrombosis [7].  After stenting, a re-endothelialization process 
occurs and patients must take anti-platelet medication until this process is complete in 
order to minimize thrombotic complications [8, 9].  For BMS, this process can take 6 – 7 
months, but for DES may take in excess of 40 months [10].  Premature discontinuation 
of antiplatelet therapy is a strong predictor of stent thrombosis and was associated with 
a 30 fold greater risk in one study [11].  The ideal duration of antiplatelet therapy remains 
unknown, although it may be longer than one year [9, 12].  Not surprisingly, the 
controversy over DES in the past five years has led to a 20% decline in their use [13].   
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Synthetic vascular grafts are another research area where thrombosis and biomaterial 
thrombogenicity are paramount.  Large diameter (greater than 7 mm) synthetic vascular 
grafts made of poly[ethylene terephthalate] (polyester or trade name DacronTM) and 
poly[tetrafluoroethylene] (PTFE) have been successful, with patency rates approaching 
90% after five years in the abdominal aortic bifurcation [14].  Smaller diameter synthetic 
vascular grafts, however, have had lower patency rates, e.g. in the femoropopliteal 
artery [15].  While patency is lowered in part by neointimal hyperplasia, both of these 
hydrophobic biomaterials engender thrombus formation on the graft lumen [16].  In 
larger vessels, a certain amount of thrombus can be tolerated, but in smaller vessels, 
like the coronary or femoropopliteal arteries, this thrombus can lead to flow cessation.  
Consequently, the development of a synthetic vascular graft for smaller diameter vessels 
remains a challenge [16, 17].   
Many studies have demonstrated that certain biomaterials or surface coatings are more 
thrombogenic than others [18-20].  Poly[ethylene oxide] (PEO) is a polymer that can be 
adsorbed onto surfaces and it has been shown in vitro that surfaces coated with PEO 
have reduced protein and cellular adsorption [21].  PEO containing block copolymers are 
a promising biomaterial, but have limited blood compatibility due to the non-PEO phase.  
PEO networks or hydrogels, by themselves, do not possess the mechanical properties 
required in many applications [22].  Polyurethanes, whose problems with in vivo 
degradation are being overcome by modifications to make them carbonate-based, are 
now being used for hemodialysis access with a one year patency rate of 66.7% [16, 23].  
Albumin coated surfaces have been produced with encouraging in vitro results, but 
clinical studies failed to show improved performance over non-coated vascular 
prostheses [24].  Heparin, given its strong anticoagulative properties, has been 
examined as a potential surface coating.  However, heparin-coated Dacron grafts did not 
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show improved patency over uncoated expanded PTFE (ePTFE) at 5 years in one 
clinical trial [15].  Elastins have been investigated as a surface covering in order to 
passivate blood-contacting surfaces after the observation that, as part of the vascular 
wall, elastin elicits minimal platelet adhesion and aggregation [25].  Thus far, elastin 
coated PTFE grafts have demonstrated low thrombogenicity in a primate ex vivo shunt 
model [17], although no large scale clinical trial has been done.  Poly[vinyl alcohol] 
(PVA) hydrogels exhibit hydrophilic properties.  One study has shown that because of 
the hydrophilicity of PVA cryogels, cell adhesions proteins did not adsorb to PVA 
hydrogels and cells were therefore unable to attach [26].  The inability of cells to attach 
to PVA hydrogels could be useful in vascular applications where platelet adhesion is 
undesirable.  One in vitro study of a PVA cryogel prosthetic venous valve with whole 
porcine blood showed that DacronTM coated valves were more thrombogenic than 
uncoated PVA cryogel valves [27].  No other published data regarding the 
thrombogenicity of this biomaterial is currently available. 
9.1.2 Biomaterial Thrombogenicity Tests 
Virchow’s triad describes the three controlling factors for coagulation in vivo as 
endothelial injury, stasis, and hypercoagulability of the blood [1].  While arterial 
thrombosis can be influenced by these factors, it occurs through different mechanisms 
and under very different flow conditions that include high shear [1, 28].  Currently, there 
is no standard thrombogenicity test for new materials [29].  As a result, many different 
kinds of thrombogenicity and hemocompatibility tests with different methods, endpoints, 
and results have been published; a brief summary of some of these methods is 
presented here.  Perhaps the simplest test is an incubation or binding study wherein the 
biomaterial is incubated with blood or plasma for a specified time [19, 29].  While these 
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tests can provide useful information about cell adhesion and protein adsorption, they fail 
to take into account shear, which is known to influence thrombus growth [28, 30].  The 
Modified Chandler loop has been used to compare platelet adhesion and activation 
among stent coatings [20, 31].  In this test, stents (or any tubular material section) are 
deployed inside tubes which are connected at both ends to form an annulus.  The tube is 
then filled with blood and the entire loop is made to rotate for a fixed amount of time – 
causing passive flow of the blood over the stent without the use of a pump that could 
damage red blood cells or activate platelets [32].  A common system for investigations 
into platelet adhesion is the parallel plate flow chamber.  These systems can be used to 
perfuse blood at varying shear rates and allow for visualization of flow throughout the 
experiment [29, 33].  While useful for certain types of investigations, few of the published 
reports of current in vitro flow loops are run to the clinically relevant endpoint of complete 
occlusion [34, 35].  Animal models are another method of evaluating biomaterials 
although they tend to be more expensive and time consuming than in vitro tests.  
Several common models used in the evaluation of blood contacting devices include 
sheep, pigs, and dogs [36-38].  In lieu of surgical implantation, ex vivo shunts can be 
used to evaluate different biomaterials.  Baboons and dogs are typical animal models for 
ex vivo shunt experiments [35, 39, 40]. 
9.2 Methods 
9.2.1 Blood Collection 
Porcine blood is chosen for these experiments because it is readily available in the 
necessary quantities and because thrombus has been shown to form with both human 
and porcine blood when run at similar flow conditions [30].  Porcine blood was obtained 
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from a local abattoir (Holifield Farms of Covington, GA) using the method described by 
Ku et al. [28].  Briefly, one liter jars were prepared with 3500 USP heparin sodium (APP 
Pharmaceuticals).  Immediately after sacrifice, blood was collected during 
exsanguination and 1 L was transferred into the jar with heparin after removing any 
particulate matter from the top.  Blood was brought to the laboratory in a thermally 
insulated case in order to minimize temperature variations.  The jars were then placed 
onto an orbital mixer table in order to reduce separation of the blood while the flow loop 
was prepared.  Immediately before testing, blood was gently mixed by rotating the jar of 
blood several times to ensure uniformity. 
9.2.2 In Vitro Flow Loop 
Blood was made to flow through the gravity fed system shown in Figure 9.1 at room 
temperature.  Three independent flow loops were run simultaneously with the following 4 
cm long test sections at the outlet which flowed into the bottom reservoir: polyester 
(negative control), no test section (positive control), and 20% PVA cryogel.  All tubing in 
which blood flowed downward was made of silicone (except test sections) and 4 mm in 
inner diameter, except for a connector piece between the top reservoir spout and the 
downward flowing silicone tube.  The height of the upper reservoir, 63 cm, was chosen 
in order to give initial flow rates that are similar to those found in the human left main 
coronary artery [41].  Polyester test sections of 4 mm inner diameter were cut from a 
large piece of commercially available polyester and hand sewn with surgical grade 
polyester sutures.  Consistent polyester test sections diameters were achieved by tightly 
sewing the polyester material onto a 4 mm metal rod which was subsequently removed.  
PVA cryogel tubes were prepared using metal and nylon molds with a 4 mm inner 
diameter as described in Section 2.2.1 of this dissertation.  Roller pumps (Cole Parmer) 
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were used to return blood to the top reservoir in 6 mm diameter silicone tubing.  The 
roller pump for each flow loop was controlled independently and the flow rate was 
adjusted manually in order to maintain each reservoir at an appropriate and constant 
level.  Flow rate was read off the roller pump controller display every 10 minutes to an 




Figure 9.1: In vitro flow loop for thrombogenicity testing. 
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All three flow loops were run simultaneously (to minimize any potential blood variability 
with time) with a staggered start in order to allow time for measurement taking and flow 
rate adjustments of each flow loop.  Tests were run until there was complete flow 
cessation in the polyester test section or until such a point when complete flow cessation 
seemed unlikely.  The location of the occlusion was verified to be in the test section by 
removing the polyester piece and verifying that flow would reinitiate without that section 
present.  The other two flow loops (no test section and 20% PVA cryogel) were then run 
to match the time of the occlusion of the polyester test section and a final flow rate was 
noted.  The test was run seven times with blood from seven different porcine donors. 








π          (9.1) 
where Q is flow rate and r0 is the radius of the test section.  Additionally, the Reynold’s 







        (9.2) 
where ρ is blood density (1025 kg/m3), µ is blood viscosity (0.0038 kg/ms), and D is the 
test section diameter.  This experimental apparatus controls for shear by using identical 
setups in each loop and controls for blood hypercoagulability by using blood from the 
same donor and running experiments simultaneously.  Differences in material 
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thrombogenicity can therefore be elucidated because the flow loops are otherwise 
identical.   
9.2.3 Blood Counts 
Within 30 minutes of test completion, the blood from each individual flow loop was 
allowed to collect into either the top or bottom reservoir.  This blood was then mixed 
gently to ensure uniformity and a sample of approximately 1.8 mL was collected and 
placed into a sterile container.  A 1.8 mL sample was also collected from blood which 
had not gone through the flow loop and instead had remained on the orbital mixer table 
during the experiment.  All four samples were then taken to the Stamps Health Services 
for testing on an Excell 22 Auto Hematology Analyzer (Drew Scientific).  Each sample 
was processed twice and the average values are reported.    
9.2.4 Histology 
Immediately after test completion, polyester and PVA cryogel test sections were rinsed 
gently in phosphate buffered saline to remove any non-adherent material.  Test sections 
were then placed into containers of 10% formalin for fixation for a period of no less than 
24 h in order to ensure that the entire sample was completely fixed.  After fixation, 
samples were prepared for histological processing in one of two orientations – 
longitudinal or axial.  Axial samples were cut into three sections: proximal, medial, and 
distal.  Samples were processed in a series of alcohol and xylene baths in an Excelsior 
ES Tissue Processor (Thermo Scientific).  When processing was complete, samples 
were placed in paraffin wax in a heated vacuum chamber overnight in order to allow the 
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paraffin to fully infiltrate the samples and facilitate slide preparation.  Samples were then 
embedded in paraffin wax and brought to room temperature.   
Samples were cut on a Microm 355H microtome in 5 µm sections and placed onto glass 
slides.  Once dry, slides were deparaffinized with an Autostainer XL (Leica 
Microsystems).  Slides were then stained using Carstair's method [42] as outlined below: 
1. Rinse with distilled water 
2. Mordant sections in 5% ferric alum for 10 minutes and rinse in tap water 
3. Stain with Harris’ hematoxylin for 5 minutes and rinse in tap water 
4. Stain in picric acid-orange G solution for 30 minutes (up to one hour) 
5. Rinse once with distilled water 
6. Stain in ponceau fuchsin for 5 minutes 
7. Rinse once in distilled water 
8. Differentiate with 1% phosphotungstic acid for 2 minutes and rinse well in distilled 
water 
9. Stain with aniline blue solution for 10 minutes (up to one hour) 
10. Rinse several times in distilled water 
With Carstair’s method, fibrin appears red, platelets appear blue-gray to navy, red blood 
cells appear clear yellow, muscle appears red, and collagen appears bright blue.  After 
staining, samples were protected with a standard coverslip and photographed on a 





9.3.1 In Vitro Flow Loop & Flow Rates 
Of the seven tests run, five of the polyester samples occluded completely with an 
average time to occlusion of 71 ± 40 minutes.  In the two tests that had no occlusion in 
the polyester test section, the flow rate was significantly reduced.  The flow rates versus 
time for the tests in which the negative control did completely occlude are shown in 
Figure 9.2.  Due to the high variability between samples, the time axis was normalized 
by dividing by the final time and the flow rate was normalized by dividing by the initial 
flow rate.  Final normalized flow rates for all tests are given in Table 9.1.  Statistically 
significant differences were seen between the negative control and the positive control 
and between the negative control and the 20% PVA cryogel, p<0.05.  No statistically 
significant differences were seen between the positive control and the 20% PVA cryogel.  
After testing and once the blood was removed from the tubes, small amounts of white 
thrombus could be seen on the 4 mm silicone tubing at the junction between the upper 
reservoir and the downward flowing tube or at the junction of the 4 mm silicone tube with 
the test section.  This thrombus tended to form equivalently in all flow loops. 
 
Table 9.1: Final normalized flow rates. 
 Polyester 
(neg. control) 




Tests to Occlusion (n=5) 0.00 ± 0.00 0.72 ± 0.14* 0.61 ± 0.19* 
All Tests (n=7) 0.08 ± 0.14  0.76 ± 0.14* 0.64 ± 0.17* 




Figure 9.2: Normalized flow rate (current flow rate over initial flow rate) versus 
normalized time (current time over final time) for all materials from tests in which the 
negative control completely occluded.  
 
 
Initial flow rates for all samples varied between 300 and 400 mL/min.  Using Equation 
9.1, the initial shear rate in the test section varied between 800 s-1 and 1000 s-1.  Using 
Equation 9.2, initial Reynold’s Number varied between 430 and 570, which is similar to 
the maximum flow conditions in the human left main coronary artery [41] and justifies the 
assumption of Poiseuille Flow.   
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9.3.2 Blood Counts 
Blood counts were obtained for all tests in which the negative control completely 
occluded, except for one sample due to a logistical problem (n=4).  Hematocrit, platelet 
concentration, and mean platelet volume are shown for each flow loop and for blood that 
was not put into the test apparatus in Table 9.2.  Two hematocrit readings and one mean 
platelet volume reading were not available as the hematology analyzer could not provide 
readings for these samples.  There were no statistically significant differences between 
the groups in the reported measures.   
 









(1000/µL) 111 ± 21 102 ± 56 130 ± 35 115 ± 23 
Mean Platelet Volume 
(fL) 9.15 ± 0.69 9.50 ± 0.71 9.64 ± 0.53 9.98 ± 0.51 
Hematocrit (%) 45.4 ± 1.6 46.6 ± 1.6 46.1 ± 1.7 45.3 ± 1.7 
Mean ± standard deviation.   
 
9.3.3 Histology 
Polyester and 20% PVA cryogel test sections from the experiments when the polyester 
sample completely occluded were processed for histology.  Test sections from three 
experiments were prepared in an axial orientation and the remaining two were prepared 
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in a longitudinal orientation.  Microscopic images of all these samples are shown in 
Figure 9.3 to 9.10.  Generally, thrombus was persistent throughout the polyester test 
sections with completely occlusive thrombi forming at different locations in each 
experiment.  Thrombus that consisted mostly of platelets, red blood cells, and collagen 
can be seen attached to the polyester fibers, which appear as white triangles with 
rounded edges in cross section.  Small amounts of thrombus were present on PVA 
cryogel test sections as well although PVA cryogel test sections generally had much less 
thrombus than polyester test sections.  Due to the differences in stiffness of the 
polyester and thrombus materials, images of the thrombus show gaps where the 
material fragmented during the sectioning process.  Since PVA cryogels are similar in 
stiffness to soft tissue, sample fragmenting was not a problem during sectioning of those 





Figure 9.3: Polyester test section from experiment on Feb. 1, 2010 in axial orientation.  
Images (a) and (b) are from the proximal region, (c) and (d) from the medial region, and 
(e) and (f) from the distal region.  Images (a), (c), and (e) were taken with a 2X objective 
while images (b), (d), and (f) were taken with a 40X objective.  An occlusive thrombus 




Figure 9.4: PVA cryogel test section from experiment on Feb. 1, 2010 in axial 
orientation.  Images (a) and (b) are from the proximal region, (c) and (d) from the medial 
region, and (e) and (f) from the distal region.  Images (a), (c), and (e) were taken with a 
2X objective while images (b), (d), and (f) were taken with a 40X objective.  No thrombus 




Figure 9.5: Polyester test section from experiment on Feb. 8, 2010 in axial orientation.  
Images (a) and (b) are from the proximal region, (c) and (d) from the medial region, and 
(e) and (f) from the distal region.  Images (a), (c), and (e) were taken with a 2X objective 
while images (b), (d), and (f) were taken with a 40X objective.  A slightly fragmented 
occlusive thrombus consisting of platelets, red blood cells, and collagen can be seen in 




Figure 9.6: PVA cryogel test section from experiment on Feb. 8, 2010 in axial 
orientation.  Images (a) and (b) are from the proximal region, (c) and (d) from the medial 
region, and (e) and (f) from the distal region.  Images (a), (c), and (e) were taken with a 
2X objective while images (b), (d), and (f) were taken with a 40X objective.  A small 
amount of adherent thrombus consisting of platelets, red blood cells, and collagen can 




Figure 9.7: Polyester test section from experiment on Feb. 24, 2010 in axial orientation.  
Images (a) and (b) are from the proximal region, (c) and (d) from the medial region, and 
(e) and (f) from the distal region.  Images (a), (c), and (e) were taken with a 2X objective 
while images (b), (d), and (f) were taken with a 40X objective.  An occlusive thrombus 




Figure 9.8: PVA cryogel test section from experiment on Feb. 24, 2010 in axial 
orientation.  Images (a) and (b) are from the proximal region, (c) and (d) from the medial 
region, and (e) and (f) from the distal region.  Images (a), (c), and (e) were taken with a 
2X objective while images (b), (d), and (f) were taken with a 40X objective.  No thrombus 




Figure 9.9: Polyester [(a), (c), and (e)] and PVA cryogel [(b), (d), and (f)] test sections 
from experiment on March 1, 2010 in longitudinal orientation.  Flow is from right to left.  
Images (a) and (b) were taken with a 2X objective, (c) and (d) with a 20X objective, and 
(e) and (f) with a 40X objective.  An occlusive thrombus can be seen in the polyester test 




Figure 9.10: Polyester [(a), (c), and (e)] and PVA cryogel [(b), (d), and (f)] test sections 
from experiment on March 8, 2010 in longitudinal orientation.  Flow is from right to left.  
Images (a) and (b) were taken with a 2X objective, (c) and (d) with a 20X objective, and 
(e) and (f) with a 40X objective.  An occlusive thrombus can be seen in the polyester test 




Using this gravity-fed flow loop system, PVA cryogels outperformed flow-matched 
polyester controls by having a higher final relative flow rate.  While most of the polyester 
test sections occluded (five of seven), the flow rates in the loop with no test section and 
in the PVA cryogel loop dropped by only 30%.  This 30% reduction in flow rate was due 
to thrombus forming on the silicone tubing (not test sections) near junctions and 
occurred evenly in all flow loops.  As such, it was deemed irrelevant to the final 
conclusions of the experiment.  Furthermore, PVA cryogel test sections were not 
statistically different from the flow loop with no test section in terms of final flow rate – 
suggesting that the PVA cryogel had no effect on thrombus formation.  This 
experimental setup, which matched physiological flow conditions of the human left main 
coronary artery and showed complete occlusion of polyester test sections, mirrored the 
clinical experience of thrombotic occlusion in small diameter synthetic vascular grafts 
[21].  This test provides a benchtop verification method for comparison of biomaterial 
thrombogenicity that uses the clinically relevant endpoint of complete occlusion and 
takes into account flow, a factor which is known to influence thrombus growth [28].  
Histology confirmed flow rate observations that large amounts of thrombus formed in the 
polyester test sections while the PVA cryogel test sections remained mostly clear of 
thrombus.  In the future, it would be interesting to compare PVA cryogels directly to 
PTFE and additionally test covered stents in place of tubes.   
Previous studies of PVA-coated tubing have shown an increase in platelet consumption 
with a canine four day ex vivo shunt model [35, 39].  In the present study however, no 
statistically significant differences in platelet concentration or mean platelet volume were 
noted for the PVA cryogel tubes.  While it is possible that the time frame studied is too 
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short to obtain measureable differences (large differences in platelet concentration were 
typically noted beyond day one of the ex vivo shunt experiments), the nature of in vitro 
blood experiments limits the maximum experiment duration.  Furthermore, the PVA 
cryogels in the present study were made without the use of a cross-linking agent and 
may not incite platelet consumption as in previous studies.  Future work, including ex 
vivo shunt experiments, with the current PVA cryogels would provide useful information 
on their thrombogenicity, e.g. platelet consumption, beyond the two hour time period 
studied here.   
Because of the large platelet presence in the occluding thrombus that formed in the 
polyester test sections, one might expect the platelet concentration of that blood to be 
significantly lower after testing than the other blood samples.  However, by estimating 
the clot size and composition, it can be shown that the number of platelets in the clot 
represents less than 5% of the total platelets in the blood.  Such a small change in 
platelet concentration is well within the experimental error of the hematology analyzer 
(up to 19% for two consecutive readings of the same blood sample) and therefore 
undetectable by these methods. 
One limitation of the current study is that it was conducted with porcine, and not human, 
blood.  While human blood is more directly relevant, porcine blood has a number of 
similarities with human blood and has been used extensively in thrombosis research [28, 
43, 44].  Pigs and humans have similar coagulation and fibrinolytic systems [44].  
Furthermore, porcine blood may be considered hypercoagulable when compared to 
human blood because of higher levels of several coagulation factors (IX, XI, and XII) and 
lower activity of protein C [43, 44].  Additionally, this study would have been difficult to 
complete with human blood given the volume of blood used.  Future work could include 
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miniaturizing the experimental setup in order to use a smaller amount of blood that could 
be more reasonably donated by humans.   
In conclusion, this gravity-fed flow loop system represents a new way to test biomaterial 
thrombogenicity to the clinically relevant endpoint of total occlusion before moving to 
expensive animal trials.  The results presented here show that 20% PVA cryogels are 
less thrombogenic than polyester – a material which is already used as a synthetic 
vascular graft.  Since the PVA cryogels had similar final flow rates as the flow loop with 
no test section, they are considered to be relatively non-thrombogenic based on this test.  
PVA cryogels may represent a new material or coating option for blood-contacting 
medical devices given their low thrombogenicity.  Further study of thrombogenicity in 
animal models is recommended to understand the long-term effects of blood contact 
with this material.   
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Chronic venous insufficiency (CVI) and its sequelae are present in nearly 27% of adults 
[1].  Patients with CVI have reduced blood flow to the heart which causes venous 
pooling, pain, and reductions in quality of life [2].  One of the main causes of CVI is the 
failure of native vein valves to prevent retrograde flow [2].  A prosthetic vein valve would 
represent an alternative treatment option for patients, especially those who are ineligible 
for other treatments such as valve repair or transplant [3].  Several prosthetic vein valves 
are in the design and testing phase, although none have arrived to market yet [4].  A 
major milestone towards the development of a prosthetic vein valve is testing of patency 
(allowing forward flow) and competency (preventing retrograde flow) in an animal model.   
10.2 Methods 
10.2.1 Animal Model & Device Description 
The sheep external jugular vein is chosen as an animal model because the site is easy 
to access through open surgery; its size is similar to veins in the human leg; and to 
facilitate direct comparison with previous studies [4].  The prosthetic vein valve studied 
here, 10 mm inlet diameter, is made from a polyvinyl alcohol (PVA) cryogel and is 
described in detail elsewhere [4-7].  Previous animal studies have shown that proper 
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apposition of a prosthetic valve to the vein wall is highly important for maintaining 
patency [4].  To that end, a balloon-expandable stent was deployed in the valve inlet as 
seen in Figure 10.1 and Figure 10.2 after the vein valve was placed.  In order to maintain 
material consistency and avoid exposure of potentially thrombogenic metal to the blood, 
PVA cryogel covered stents were used.  The PVA cryogel covered stents used here 





Figure 10.1: Diagram of percutaneous covered stent deployment in prosthetic vein valve 




Figure 10.2: View of venotomy (left) and covered stent being introduced into vein along 
guide wire (right). 
 
 
10.2.2 Device Implantation 
A full description of the vein valve deployment is given by Midha [4].  Briefly, the sheep 
was anesthetized and a small incision (~2 cm) was made approximately 15 cm upstream 
of the final covered stent-valve location as shown in Figure 10.3.  Once the connective 
tissue was moved aside and the vein located, a venotomy was made which allowed for 
insertion of the 18 Fr delivery sheath and dilator device as seen in Figure 10.2.  The 
sheath and dilator were then advanced to the desired location where the sheath was 
retracted and the vein valve deployed.  Once the vein valve delivery system was fully 
retracted, the PVA cryogel covered stent was deployed as shown in Figure 10.1 and 
Figure 10.2.  The covered stent was hand-crimped onto the balloon catheter and 
advanced to the vein valve location while being visualized with a fluoroscope.  The 
balloon was inflated with an insufflator until the valve inlet and stent were properly 
apposed against the vein wall.  The balloon was then deflated and withdrawn – leaving 
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the valve and covered stent in place.  In this study, four vein valve-covered stent devices 
were implanted in three sheep, identified as 482, 827 (left and right side), and 828.  All 
sheep received 325 mg aspirin for one week before surgery and continued to receive the 








Figure 10.3: Healed implantation incision (left) and distance from incision site to valve 
and covered stent (right).   
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10.2.3 Venogram Follow-Up 
Venograms were completed at one week intervals in order to assess device patency.  
Under anesthesia, radio-opaque contrast media was injected just upstream of the 
device.  The path of the contrast media was followed under a flouroscope to visualize 
blood flow.  If the device was patent, the contrast media would appear as a single 
stream through the external jugular vein.  If the device was no longer patent, contrast 
media would not flow through the device, but rather around the device and through 
collateral veins.   
10.3 Results 
There were no procedural complications during implantation of the valves or covered 
stents.  All four devices were patent at 2 weeks (Figure 10.4) with one remaining patent 
until 4 weeks.  After sacrifice, devices were explanted without difficulty and examined 
macroscopically.  There was no fibrotic encapsulation or inflammatory response by 
gross pathological examination.  Covered stent membranes were intact and had no 
visible tears, punctures, or separation from the stent metal.  One explanted covered 









Figure 10.4: Two week patency venograms from (a) sheep 482, (b) sheep 827 left, (c) 
sheep 827 right, and (d) sheep 828.  No collateral flow is seen as the contrast passes 
straight through the covered stent and vein valve.  There was some slight extravasation 





Figure 10.5: Explanted vein valve and covered stent.  There are no visible tears in the 
PVA cryogel membrane or separation of the stent metal from the PVA cryogel. 
 
10.4 Discussion 
The work presented here is the first animal implantation of a PVA cryogel covered stent 
and represents a major step forward in the development of these devices because it 
demonstrates the ability to make and deploy PVA cryogel covered stents in vivo.  PVA 
cryogel covered stents were made by hand, manually crimped onto a balloon catheter by 
a surgeon, and then deployed at the vein valve inlet site.  The delivery catheter used 
was 18 Fr and is larger than what would be used for a covered stent implantation.  While 
the PVA cryogel covered stent could have been delivered with a smaller delivery sheath, 
the size and geometry of the prosthetic vein valve necessitated the larger size.  After 
explantation, covered stents were inspected and the membranes were all intact – 
providing evidence for the mechanical durability of this material in an in vivo setting.  
Also of note is that there was no fibrotic or inflammatory response by gross pathological 
examination.   
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One limitation of this study, in terms of the covered stents, was that it was completed in 
veins and not arteries.  While the sheep external jugular vein is an appropriate location 
for testing vein valve patency, direct analysis of covered stent thrombogenicity is not 
possible because of the differences between clot formation in arteries and veins [8].  
Venous thrombus, commonly referred to as red thrombus, tends to form at areas of 
stasis and contain more red blood cells than arterial thrombus [8].  Arterial thrombus, 
commonly referred to as white thrombus, forms at high shear and contains large 
amounts of platelets and fibrin, but relatively few entrapped red blood cells [9].  To truly 
evaluate the thrombogenicity of PVA cryogel covered stents for treating atherosclerosis, 
future animal trials should deploy the covered stents in arteries. 
Regarding prosthetic venous valves, an average patency of 2.5 weeks (maximum 4 
weeks) in sheep is on par with several completed studies [10, 11] and surpasses at least 
one other study [12].  Occlusion in the covered stents and vein valves could have been 
caused by imperfections from the hand-manufacturing of both components.  Future work 
should include the incorporation of good manufacturing practices in order to ensure 
consistency across the devices and remove this potential issue.  As this was the first 
experience with implantation of PVA cryogel covered stents/vein valves and the delivery 
system was custom-made for each implantation, there was some variability between the 
implantations as the operators gained experience in deploying these devices together.  
Future animal trials should include a larger number of animals and be completed in a 
more consistent manner in order to elucidate the exact causes and mechanisms of 
device occlusion and improve next-generation devices. 
In conclusion, the present study showed the feasibility of delivering PVA cryogel covered 
stents via catheter in vivo.   After device explantation, there was no gross inflammation 
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or fibrotic response.  Covered stent membranes were intact – providing evidence for the 
mechanical durability of PVA cryogel covered stents.  Future studies of PVA cryogel 
covered stents should include implantation into an arterial model.   
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Part 3: Conclusions, Significance, and Future Directions 
 
The gravity-fed flow loop system presented in Chapter 9 represents a new method for 
testing biomaterial thrombogenicity that includes the clinically relevant endpoint of 
complete occlusion.  Using this test, small diameter polyester test sections failed by 
complete occlusion – mirroring the clinical experience with small diameter polyester 
vascular grafts as arterial bypasses.  By mimicking flow conditions in the human left 
main coronary artery, the method gains relevancy for stent and vascular graft materials 
that are in a similar environment.  With this gravity-fed system, measurements of flow 
rate can be obtained up until complete occlusion.  The use of flow rate and complete 
occlusion as a means of comparison may be more clinically relevant than previous tests 
which evaluate thrombogenicity by platelet activation assays and scanning electron 
microscope images of relatively small amounts of thrombus deposition.  In the future, the 
flow system geometry could be modified to investigate thrombogenicity in other regions 
of the vasculature and other types of blood contacting devices.   
Using this test method, 20% PVA cryogel tubes were found to be less thrombogenic 
(higher final flow rate and less thrombus upon histological examination) than flow-
matched polyester test sections.  The final flow rates in the PVA cryogel flow loops were 
not found to be statistically different from a flow loop which had no test section – 
suggesting that the PVA cryogel tube had no effect on thrombus formation within the 
system.  While platelet consumption has been a concern for PVA hydrogel materials in 
the past, these results showed no difference in mean platelet volume or platelet 
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concentration between blood tested with PVA cryogels and blood that was not tested in 
the flow loop system.   
In Chapter 10, PVA cryogel covered stents were deployed into sheep external jugular 
veins via catheter as part of a study on prosthetic vein valves.  The devices were all 
patent at 2 weeks; this result matched and surpassed several previously published 
studies of prosthetic vein valves.  After sacrifice, gross pathological examination showed 
no inflammatory or fibrotic response at the deployment site.  PVA cryogel membranes 
were intact after explantation – providing evidence of the in vivo durability of PVA 
cryogel covered stents.  Even though covered stents were deployed into veins (and not 
arteries), this work represents a significant step forward in the development of these 
devices because the feasibility of making and deploying these devices was 
demonstrated for the first time.   
Overall, the results in Chapters 9 and 10 point to the relatively low thrombogenicity of 
PVA cryogels as measured in vitro and in vivo.  The outcomes of both of these tests 
establish the feasibility of using PVA cryogels in blood-contacting medical devices – 
specifically as covered stent membranes.  It is recommended that future work focuses 
on animal trials, e.g. porcine, that can evaluate PVA cryogels in terms of restenosis and 
thrombosis.   
 
 
